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ABSTRACT 
Jie Xie 
 
TSG-6: AN INDUCIBLE MEDIATOR OF PARACRINE ANTI-INFLAMMATORY 
AND MYELOPROTECTIVE EFFECTS OF ADIPOSE STEM CELLS 
 
Tumor necrosis factor-induced protein 6 (TSG-6) has been shown to 
mitigate inflammation. Its presence in the secretome of adipose stem / stromal 
cells (ASC) and its role in activities of ASC have been overlooked. This thesis 
described for the first time the release of TSG-6 from ASC, and its modulation by 
endothelial cells. It also revealed that protection of endothelial barrier function 
was a novel mechanism underlying the anti-inflammatory activity of both ASC 
and TSG-6. Moreover, TSG-6 was found to inhibit mitogen-activated lymphocyte 
proliferation, extending the understanding of its pleiotropic effects on major cell 
populations involved in inflammation.  
Next, enzyme-linked immunosorbent assays (ELISA) were established to 
quantify secretion of TSG-6 from human and murine ASC. To study the 
importance of TSG-6 to specific activities of ASC, TSG-6 was knocked down in 
human ASC by siRNA. Murine ASC from TSG-6-/- mice were isolated and the 
down-regulation of TSG-6 was verified by ELISA. The subsequent attempt to 
determine the efficacy of ASC in ameliorating ischemic limb necrosis and the role 
of TSG-6, however, was hampered by the highly variable ischemic tissue 
necrosis in the BALB/c mouse strain. 
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Afterwards in a mouse model of cigarette smoking (CS), in which 
inflammation also plays an important role, it was observed, for the first time, that 
3-day CS exposure caused an acute functional exhaustion and cell cycle arrest 
of hematopoietic progenitor cells; and that 7-week CS exposure led to marked 
depletion of phenotypic bone marrow stem and progenitor cells (HSPC). 
Moreover, a dynamic crosstalk between human ASC and murine host 
inflammatory signals was described, and specifically TSG-6 was identified as a 
necessary and sufficient mediator accounting for the activity of the ASC 
secretome to ameliorate CS-induced myelotoxicity. These results implicate TSG-
6 as a key mediator for activities of ASC in mitigation of inflammation and 
protection of HSPC from the myelotoxicity of cigarette smoke. They also prompt 
the notion that ASC and TSG-6 might potentially play therapeutic roles in other 
scenarios involving myelotoxicity. 
 
 
 
     Keith L. March, M.D., Ph.D., Chair 
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Chapter 1. Introduction 
1.1 Inflammation and Mesenchymal Stem Cells 
Overview of Inflammation 
The inflammatory cascade begins with proinflammatory cytokine release 
from injured cells or antigen-presenting cells (macrophages or natural killer cells). 
These cytokines stimulate parenchymal cells to produce chemokines that recruit 
neutrophils and monocytes. Infiltrated neutrophils not only phagocytize 
pathogens and cell debris, but also release toxic proteases and free radicals. If 
this innate immunity does not subside timely, it may cause excessive collateral 
tissue damage. Monocytes give rise to macrophages, which engulf a large 
number of viruses and bacteria. Antigens presented by macrophages or NK cells 
activate T lymphocytes to proliferate. Cytotoxic T cells are responsible for 
eliminating foreign cells or cells infected with viruses. The proliferation of 
cytotoxic T cells can be further enhanced by helper T cells. It has been 
increasingly recognized that excessive or nonresolving inflammation contributes 
to the damage wrought by degenerative diseases such as atherosclerosis, 
obesity, diabetes, COPD, and arthritis.1-3  
 
BMSC vs. ASC 
Mesenchymal stem cells (MSC) are a heterogeneous population of cells 
that proliferate in vitro as plastic-adherent cells, have fibroblast-like morphology, 
form colonies in vitro and can differentiate into bone, cartilage and fat cells.4 
Stromal cells that fulfill these criteria have been isolated from almost every type 
of connective tissue, including bone marrow, adipose tissue, placenta, and 
umbilical cord.5 Bone marrow-derived MSC (BMSC) were discovered first and 
are the best characterized type of MSC. Adipose tissue has been identified as a 
key promising alternative source for MSC, because adipose stem or stromal cells 
(ASC) can be readily isolated in considerably larger amounts.6 As mesenchymal 
stem cells, BMSC and ASC share many biological characteristics, and have both 
been proven effective in a largely overlapping spectrum of disease applications.7-
10 That said, MSC residing in these two distinctive niches also have many 
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differences in their immunophenotype, differentiation potential, transcriptome, 
proteome, and immunomodulatory activity. For instance, ASC suppressed 
pokeweed mitogen-induced Ig production from peripheral blood mononuclear 
cells to a much greater extent than BMSC.11 ASC also outperformed BMSC at 
stimulating the secretion of the immunosuppressive cytokine IL10 by dendritic 
cells.12 The molecular mechanisms underlying these tissue-specific differences, 
however, remain unknown. 
 
Modulation of Immune Cells by MSC 
MSC are described as immune privileged cells, due to low expressions of 
class II Major Histocompatibility Complex (MHC-II) and costimulatory 
molecules.13 They also interfere with various pathways of the immune response 
by means of direct cell-to-cell interactions and soluble factor secretion. This is 
probably mediated by the multiplicity of immune mediators in the secretome of 
MSC (Figure 1, adapted from reference 14). In vitro, MSC inhibit cell proliferation 
of T cells, B-cells, natural killer cells (NK) and dendritic cells (DC), producing 
what is known as division arrest anergy.15 Moreover, MSC can stop a variety of 
immune cell functions: cytokine secretion and cytotoxicity of T and NK cells; B 
cell maturation and antibody secretion; DC maturation and activation; as well as 
antigen presentation. It is thought that MSC need to be activated to exert their 
immunomodulation activities.16 In this scenario, an inflammatory environment 
seems to be necessary to promote their effects; and some inflammation-related 
molecules such as TNFα have been implicated. It has been observed that MSC 
recruit regulatory T lymphocytes to both lymphoid organs and the graft.  
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Figure 1. Multiple proposed mechanisms of interactions between MSC and 
cells of the innate and adaptive immune systems.  
Literature from multiple groups has shown sophisticated immuno-
modulatory effects of mesenchymal stem cells (MSC) via either physical contact 
or trophic factors. However, endothelial cells, as fundamental structural blocks of 
blood vessels and barriers against leukocyte extravasation, have not been taken 
into account. Adapted from reference 14. 
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Mediators of Immunomodulation by MSC 
There is great controversy concerning the mechanisms and molecules 
involved in the immunosuppressive effect of MSC. Prostaglandin E2 (PGE2), 
transforming growth factor-β (TGFβ), heme oxygenase-1 (HO1), interleukins-6 
and 10 (IL6 and IL10), human leukocyte antigen-G5 (HIA-G5), HGF, matrix 
metalloproteinases, indoleamine-2, 3-dioxygenase (IDO), and nitric oxide (NO) 
are all candidates under investigation.14  
Many of these soluble factors such as PGE2, TGFβ, HO1, IL6, IL10, HIA-
G5, and HGF are constitutively produced by MSC.17-24 The secretion of certain 
moledules can be further increased when MSC are stimulated. For instance, 
TNFα and IFNγ have been shown to increase the production of PGE2 by MSC, 
which in turn mediates the suppressive effects of MSC on TNFα secretion from 
mature DC, IFNγ secretion from T lymphocytes, and PHA-induced lymphocyte 
proliferation.18 IL6 has also been reported to be involved in the inhibitory effect of 
MSC on mixed lymphocyte reaction as well as the differentiation of bone-marrow 
progenitor cells into dendritic cells (DC).25 Another important molecule HlA-G5 
has been shown to regulate acitivity of MSC to suppress T-cell proliferation, as 
well as NK-cell and T-cell cytotoxicity, and to promote the generation of 
regulatory T cells.23 Cell contact between MSC and activated T cells induces 
IL10 production, which, in turn, has an essential role in stimulating the release of 
soluble HlA-G5 by MSC.19  
On the other hand, certain factors in MSC secretome are only released 
following crosstalk with target cells. For instance, IDO is only secreted by MSC 
when stimulated by IFNγ. IDO contributes to the inhibition of lymphocyte 
proliferation by MSC through depletion of tryptophan, which is an essential amino 
acid for lymphocyte proliferation. MSC-derived IDO was also required to inhibit 
the proliferation of IFNγ-producing TH1 cells.26 IFNγ, alone or in combination with 
TNFα, IL1α or IL1β, also stimulates the production of inducible nitric-oxide 
synthase (iNOS), which inhibits T-cell activation through the production of NO.27 
MSC from mice deficient for the IFNγ receptor IFNγR1 do not have immuno-
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suppressive activity, which further support the crucial role of IFNγ-indicible 
factors to activities of MSC.27  
In additional to these molecules, TSG-6 has recently been identified as 
mediating anti-inflammatory activities of BMSC in several inflammatory disease 
models. Its effects on different immune cells, such as lymphocytes remain 
unknown. It is therefore highly interesting to find out if TSG-6 would shed some 
new light into the sophisticated immunemodulatory effects of MSC. 
 
MSC and Vascular Barrier 
Vascular endothelium serves both as a regulator and victim in the 
inflammatory process. One critical early step of inflammation, leukocyte 
extravasation, is tightly regulated by adhesion molecules and junction proteins on 
the surface of endothelial cells.28 BMSC has been shown to inhibit VEGF-
induced permeability to dextran in vitro by increasing VE-cadherin levels and 
enhancing recruitment of both VE-cadherin and beta-catenin to the plasma 
membrane of endothelial cells.29 In addition, leukocyte adhesion and adhesion 
molecule expression (VCAM-1 and ICAM-1) were also inhibited in pulmonary 
endothelial cells (PEC) treated with conditioned media from MSC-PEC co-
cultures. By stablizing vascular endothelium in inflammation, MSC were able to 
significantly reduce leukocyte infiltration and edema in lung in a rat model of 
hemorrhagic shock-induced lung injury.30 Despite these previous descriptions of 
proective effects of MSC on endothelial integrity, the key mediators responsible 
for activities of MSC remain yet to be found.  
Given the recently described in vivo perivascular location of both ASC and 
other MSC,31, 32 we felt that an important set of experiments, complementary to 
those above, would address the crosstalk between MSC and EC in the context of 
inflammation, especially with regard to leukocyte transmigration. These 
experiments are also described in Chapter 2.  
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1.2 Tumor Necrosis Factor-Stimulated Gene 6 (TSG-6) 
Regulation of TSG-6 Transcription 
Tumor necrosis factor alpha-induced protein 6 (TNFIP6 or TSG-6) was 
first discovered in TNFα-stimulated human foreskin fibroblasts.33 The coding 
gene for TSG-6 is located in chromosome 2q23.3. Sequences responsible for 
activation of TSG-6 transcription are located between positions -165 and -58. 
Sequencing of a 1.3-kilobase fragment of the 5'-flanking region of the TSG6 gene 
identified TATA-like and CAAT sequences near the transcription start site. In 
addition, potential binding sites for interferon regulatory factors (IRF), activator 
protein-1 (AP1), nuclear factor interleukin-6 (NFIL6), and glucocorticoid response 
elements (GRE) have been identified in the 5'-flanking region (Figure 2A) and 
may be involved in TNFα and IL1β-induced TSG-6 activation, although these two 
cytokines may act through distinct pathways. The region further upstream 
(between positions -332 and -165), however, may be involved in silencing of 
TSG-6 transcription.34  
The inducibility of TSG-6 is regulated differently depending on the cell 
type. In addition to fibroblasts, Many other types of primary cells were also 
capable of increasing TSG-6 production under a variety of stimulatory conditions, 
such as neutrophils (stimulated by lipopolysaccharides), smooth muscle cells (by 
mechanical strain), and cumulus oocyte complex (by ovulation) (reviewed in 35). 
Occasionally, certain types of cells have been shown to produce TSG-6 
constitutively, such as human amniotic membrane epithelial and stromal cells.36 
Interestingly, cycloheximide (protein synthesis inhibitor) did not interfere with 
transcriptional activation of TSG-6 by TNFα in fibroblasts, but abrogated growth 
factor-induced TSG-6 expression in smooth muscle cells. This suggests that 
pathways regulating TSG-6 expression may vary among different cell types.34, 37  
More than 400 single nucleotide polymorphisms (SNP) have been noted in 
human TSG-6 gene. Nentwich et al reported a particular SNP that involves a 
non-synonymous G to A transition at nucleotide 431, resulting in an Arg to Gln 
alteration in the CUB module. Although modeling indicated that the amino acid 
change might lead to functional differences, no association was found between 
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the polymorphism and susceptibility to osteoarthritis in the 400 osteoarthritis 
cases and 400 controls studied. 38  
 
Structure and Binding Partners 
In fibroblasts, after cleavage of the signal peptide and N-glycosylation, 
TSG-6 is secreted as a 35 kDa glycoprotein.39 As a member of the hyaluronan-
binding protein family, TSG-6 protein consists of two structural domains: a N-
terminal hyaluronan-binding link module, the characteristic domain of this family 
of proteins, and a C-terminal CUB domain (Figure 2B). NMR spectroscopy has 
revealed that the Link module comprises two triple-stranded antiparallel β-sheets 
and two α-helices arranged around a large, well-defined hydrophobic core. Other 
proteins sharing the link module with TSG-6 include CD44, aggrecan, and 
versican. Via the link module, TSG-6 interacts with a broad spectrum of GAG 
(glycosaminoglycan) and protein ligands, including HA (hyaluronan), C4S 
(chondroitin-4-sulphate), heparin, IαI (inter-α-inhibitor), CD44, aggrecan, 
versican, TSP1 (thrombospondin-1), and PTX3 (pentraxin-3).39-47 On the other 
hand, TSG-6 also binds to fibronectin via the CUB module, but not the link 
module, and mediates fibronectin interactions with other matrix components and 
cells.48  
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Figure 2. Gene and protein structure of TSG-6.  
(A) The TSG-6 promoter contains potential binding sites for interferon regulatory 
factors (IRF, at -129, -947, and -1016), activator protein-1 (AP-1, at -126), 
nuclear factor interleukin-6 (NFIL-6, at -115 and -1291), and glucocorticoid 
response elements (GRE, at -629 and -1148). (B) TSG-6 protein consists of a 
link module (Gly36 to Cys127) and a CUB module (Gly136 to Phe240) with two 
potential glycosylation sites (ball and stick).  
  
	   9 
TSG-6 in Inflammatory Diseases 
The inducibility of the TSG-6 gene by the proinflammatory cytokine TNFα 
suggested a possible association with inflammatory processes and a potential 
role in inflammatory diseases. Indeed, TSG-6 was absent in normal synovial 
fluids but became readily detectable in synovial fluids of patients presenting with 
various joint diseases including rheumatoid arthritis, osteoarthritis, Sjogren’s 
syndrome, polyarthritic gout, and osteomyelitis.49 This is consistent with the in 
vitro observation that synovial cells isolated from patients with rheumatoid 
arthritis expressed TSG-6 constitutively and responded to stimulation with either 
IL-lβ or TNFα with an additional upregulation of TSG-6 expression.49 Besides 
synovial fluid, TSG-6 was also found to be high in the sera of patients with 
bacterial sepsis and systemic lupus erythromatosus.50  
 
Use of Recombinant TSG-6 Protein in Animal Models of Inflammation 
The in vivo anti-inflammatory effect of TSG-6 was recognized more than a 
decade ago first in a skin inflammation model, in which local injection of 10 µg 
recombinant human TSG-6 protein significantly attenuated both carrageenan and 
IL1β-induced edema and neutrophil infiltration in the subcutaneous air pouch, 
similar in magnitude to that seen with dexamethasone.51 Bioling or single amino 
acid substitutions in the N-terminal region resulted in complete loss of TSG-6 
activity, suggesting the importance of link module to the activity of TSG-6.  
Later in a proteoglycan-induced arthritis model, recombinant murine TSG-
6 were administered either intravenously or intra-articularly. Intravenous injection 
(100 µg) of rmTSG-6 induced a dramatic reduction of edema in acutely inflamed 
joints by immobilizing CD44-bound hyaluronan and, in long-term treatment, 
protected cartilage from degradation and blocked subchondral and periosteal 
bone erosion in inflamed joints. The intra-articular injection of a single dose (100 
µg) of rmTSG-6 exhibited a strong chondroprotective effect for up to 5 to 7 days, 
preventing cartilage proteoglycan from metalloproteinase-induced degradation. 
However, the onset and incidence of arthritis were not affected, nor were any 
changes in serum pro- and anti- inflamamtory cytokines observed.52 The 
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importance of TSG-6 to inflammation control was further strengthened by the 
observation that TSG-6-null mice suffered from more extensive and rapid 
cartilage degradation, bone erosion, joint ankylosis, and deformities in a 
proteoglycan-induced arthritis model.53  
 
TSG-6 and Marrow Stromal Cells 
The variety of inflammatory disease models found to be improved by TSG-
6 has rapidly increased since TSG-6 was first identified in the secretome of bone 
marrow stromal cells (BMSC). Lee et al found that intravenously delivered BMSC 
were mostly trapped in the lung and activated by TNFα to secrete TSG-6, in the 
context of cardiac injury. Knockdown of TSG-6 by siRNA led to loss of the 
therapeutic effects of BMSC on infarcted myocardium.54 Furthermore, similar to 
previous observations in arthritis model, the protective effects of BMSC and 
TSG-6 protein on myocardium were also associated with inhibition of plasmin 
activity and MMP9 activation, and reduction of neutrophil infiltration.  
Such overlap between indications of BMSC and TSG-6 has fueled 
successive efforts to substitute BMSC-based cell therapy with TSG-6-based 
cytokine therapy. In a corneal injury model, in which BMSC have previously been 
proven effective, local injection of 2 µg TSG-6 resulted in marked decrease of 
corneal opacity, neovascularization, and neutrohphil infiltration, accompanied by 
reduced proinflammatory cytokines (IL6 and IL1β), chemokines (CXCL1 and 
MCP1), and matrix metalloproteinases (MMP9).55 Similar protease suppressive 
activity, not on MMP9 but on MMP1 and MMP3, was responsible for the anti-
inflammatory function of TSG-6 produced by conjunctiva fibroblasts in a 
conjunctivochalasis model.56 Local injection of 400 ng TSG-6 also led to slower 
progression or alleviation of retinal lesions in a murine model of focal retinal 
regeneration.57 In a peritonitis model, intraperitoneous injection of 30 µg 
recombinant human TSG-6 exhibited equivalent effect as 1.6 X 106 human 
BMSC in reducing total cell numbers in the exudate.47 In addition, the anti-
inflammatory activity of TSG-6 comparable to BMSC was also demonstrated in 
an acute lung injury model.58 
	   11 
Modulation of Immune Cells by TSG-6 
As a member of the hyaluronan-binding protein family, TSG-6 consists of 
“link” and “CUB” modules. The shared structure of link modules in this protein 
family allows for binding of the TSG-6 link domain to other members such as 
hyaluronan, chondroitin-4-sulfate, proteoglycan aggrecan, and CD44.42, 44 Among 
them, CD44 was found to be a receptor for TSG-6 on macrophages mediating a 
feedback inhibition on TNFα release via interference with the NF-κB signaling 
pathway.47 Cao et al observed that neutrophil adhesion and extravasation in 
microcirculation were significantly reduced by the administration of link module of 
TSG-6 protein; and similarly, transmigration of neutrophils across endothelial cell 
monolayers in vitro was also decreased by the link module as well as the TSG-6 
holoprotein. Unfortunately, they were not able to identify any specific responsible 
molecular mechanisms since the three measured adhesion molecules (ICAM-1, 
PECAM-1, and P-selectin) of endothelial cells remain unchanged.59 
 
Protease and Extracellular Regulation by TSG-6 
Protease network regulation is another proposed mechanism of TSG-6. 
According to Wisniewski et al, TSG-6 can form a complex with inter-α-inhibitor, 
which exhibits potent anti-plasmin activity. This could explain the attenuated 
tissue damage after TSG-6 injection, since the two major destructive proteases 
released from neutrophils, matrix metalloproteinase 2 and 9 (MMP2 and MMP9), 
are activated by plasmin.51 On the other hand, the protective effect of TSG-6 may 
not be restricted to reducing inflammatory attacks but also enhancing the 
protective layer of extracellular matrix. Finally, the link module of TSG-6 has a 
strong affinity for hyaluronan, and hyaluronan-crosslinking via TSG-6 at the 
surface of synovium, cartilage, or oocyte may form a protective barrier, 
potentially preventing matrix degradation, and/or acting as a scaffold for matrix 
regeneration.44 
While previous studies of TSG-6 have primarily focused on proteases and 
extracellular matrix as its targets, we felt that it would be novel and potentially 
important to evaluate its effects on immune cells and how it contributes to the 
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anti-inflammatory effects or immunomodulation by MSC. This became an 
important motivation for several of the experiments described in Chapter 2.  
 
1.3 Cigarette Smoking-induce Myelotoxicity as an Inflammatory Disease 
Model  
Clinical Evidence for Extrapulmonary Toxicity of Smoking 
CS is one of the most prevalent life style risk factors adversely influencing 
the health of human beings. On average, one in two men and one in ten women 
are current smokers. It has been increasingly recognized that the damage from 
cigarette smoking is not only restricted to the lung but also extends to extra-
pulmonary organs, including well-established links to atherosclerosis, peripheral 
arterial disease, and cancer.60-64  
Compared to other organs, the toxicity in bone marrow caused by CS 
tends to be more insidious, with little or no clinical manifestations. This is 
probably because only 10-20% of the normal complement of hematopoietic 
progenitors is necessary to maintain hematopoiesis, and bone marrow is not 
routinely examined in otherwise healthy smokers.65, 66 Nevertheless, there has 
been accumulating evidence showing that CS is associated with an increased 
risk of bone marrow failure, myelodysplasia, and myeloid leukemia, as well as up 
to 50% reduction in survival following marrow transplantation into smokers.67-69 
 
Myelotoxicity in Animal Models 
In animal models, Khaldoyanidi et al observed that after 2 weeks of CS 
exposure, bone marrow myeloid progenitors in BALB/c mice decreased by 53% 
and the homing of hematopoietic progenitors to bone marrow after lethal 
irradiation decreased by 83%. This myelotoxicity of CS was consistent with the in 
vitro finding that formation of cobblestone areas was inhibited by nicotine 
treatment in long-term bone marrow culture and that colony formation from 
hematopoietic progenitors was inhibited by a metabolite of nicotine, cotinine.70, 71 
Although nicotine does promote extra-medullary hematopoiesis, subcutaneously 
implanted nicotine, after 3 weeks of slow release, was not able to fully 
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recapitulate the myelosuppressive effect of smoking on the bone marrow.72 
These findings underline the complexity of chemical compounds in smoke other 
than nicotine, which also play important roles in the pathogenesis of smoking 
toxicity. 
 
Mediators for Systemic Toxicity of Smoking 
Other critical factors to be considered are derivatives from body response 
to smoking, such as acute-phase proteins (APP), inflammatory cytokines and 
free radicals. Several studies have reported strong associations between 
cigarette smoking and different APP such as C-reactive protein (CRP) and 
fibrinogen.73 CRP might contribute to the increased risk of atherosclerosis and 
endothelial dysfunction in smokers, by stimulation of IL6 and endothelin-1 
production, and upregulation of adhesion molecules, promoting a cascade of 
events that can lead to clot formation and even atherosclerosis in apolipoprotein 
E-deficient mice.74 Fibrinogen may promote cardiovascular diseases through 
effects on blood viscosity, platelet aggregation, and fibrin formation.75 On the 
other hand, raised levels of plasma APP may also reflect elevations of 
inflammatory cytokines such as IL6 and TNFα, which are major inducers of APP. 
In fact, several studies have indeed shown increased levels of TNFα and IL6 in 
smokers.76, 77 In addition, Exposure to oxidant chemicals in smoke is associated 
with depletion of endogenous levels of antioxidants in the systemic compartment. 
The total plasma antioxidant capacity was significantly lower in smokers than in 
nonsmokers and an inverse relationship between cigarette consumption and 
plasma levels of vitamin C and β-carotene corrected for habitual dietary intake 
has been found.78-81 These byproducts from smoking may be just as detrimental 
as the original chemical compounds contained in the cigarette smoke. For 
instance, both CRP and TNFα are established suppressors of colony formation 
from hematopoietic progenitors.82, 83  
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1.4 Mesenchymal Stem Cells and Hematopoiesis 
BMSC & Hematopoiesis 
In bone marrow, various chemokines, extracellular matrix and adhesion 
molecules produced by stromal cells contribute to the formation of “stem cell 
niches”, which regulate homing, proliferation, differentiation, and mobilization of 
hematopoietic progenitor cells84-90. More specifically, MSC produce stem cell 
factor, Fms-like Tyrosine Kinase (FLT3) ligand, thrombopoietin, leukemia-
inhibiting factor, TGFβ, IL4, IL6, IL7, IL8, IL11, IL12, IL15, granulocyte 
macrophage (GM-) and macrophage colony stimulating factor (M-CSF).91 MSC 
also synthesize intercellular adhesion molecule-1 (ICAM-1) and vascular cell 
adhesion molecule-1 (VCAM-1), as well as laminin, fibronectin, collagen and 
proteoglycans.92, 93 This niche structure built from MSC even without other cell 
types was sufficient to maintain long-term culture initiating cells and expand 
lineage-specific colony forming units from CD34+ bone marrow cells in long-term 
bone marrow cultures.94  
 
Hematological Therapy involving BMSC 
Normal hematopoiesis in the bone marrow is subject to many 
environmental or interventional hazards, such toxins, irradiation, and 
chemotherapy. Refractory myelosuppression warrants bone marrow 
transplantation, often allogeneic, which is hampered by the severe complication 
of graft versus host disease (GVHD). The hematopoiesis-supporting and 
immunomodulatory nature of MSC makes them an ideal adjunctive therapy to 
prevent / mitigate GVHD and enhance engraftment and fast recovery of 
hematopoietic stem / progenitor cells. Numerous clinical trials have been 
conducted testing the efficacy of MSC against de novo or steroid-refractory 
GVHD. There are still considerable controversies over the outcomes, which 
seem to be affected by the patient demographics, affected organs, cell infusion 
scheme, etc. Nevertheless, the potential for MSC clinical benefit appears high. In 
one study, MSC were given 50-294 days post-transplant without co-infusion of 
hematopoietic stem cells (HSC), to functionally improve bone marrow 
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microenvironment and to further stimulate residual hematopoietic tissue. Two out 
of six patients showed rapid hematopoietic recovery, in contrast to the other 
heavily pretreated patients.95 Interestingly, in a preclinical study, human MSC co-
transplanted with human cord blood CD34+ cells in irradiated NOD/SCID mice 
were shown to promote hematological recovery despite an absence of persistent 
MSC in the bone marrow at 6 weeks post transplantation.96 This suggested that 
infused MSC could promote homing and/or proliferation of HSC via their 
constitutive secretion of various hematopoietic cytokines and immunomodulatory 
soluble factors, without chronic persistence of MSC within the recipient bone 
marrow.97  
 
ASC & Hematopoiesis 
In contrast to their counterpart in the BM, ASC have been much less 
explored in the context of hematopoiesis, possibly due to their long geographic 
distance from bone marrow in vivo. The recent discovery of hemangioblast in the 
adult adipose tissue sparked the idea that even outside the bone marrow, ASC 
may still retain important functions involved in the support of hematopoiesis.98 
Indeed, many of the critical hematopoietic cytokines from BMSC can also be 
secreted by ASC. Interestingly, Nakao and De Toni in independent studies both 
found that ASC demonstrated an even stronger benefit than BMSC in facilitating 
engraftment of HSC after mice were irradiated.99, 100 Little has been known 
regarding to whether and how ASC protect hematopoietic stem and progenitor 
cells from myelotoxins such as free radicals, inflammatory cytokines, and 
chemotherapy agents. These findings, taken together, provided the 
inspiration for the experiments concerning the effects of ASC and TSG-6 
on CS-induced myelotoxicity, described in Chapter 4.  
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Chapter 2. Inflammation Control through TSG-6: Dynamics at the 
Perivascular Niche 
2.1 Introduction 
The vascular wall formed by endothelial cells (EC) restricts passage of 
circulating molecules and inflammatory cells into the underlying tissues. This 
barrier function is critical for the maintenance of tissue homeostasis and cellular 
functions. ASC reside in perivascular niche in vivo resembling pericytes and, 
when isolated and administered back, exert potent effects against 
inflammation.31, 32 This anti-inflammatory function of ASC has previously been 
attributed mainly to the immune-modulation of various immune cells through 
either direct contact inhibition or soluble factors.14 The role of ASC in the 
regulation of vascular barrier function has rarely been explored.  
On the other hand, the distinct contrast between quiescence of ASC in the 
perivascular niche and strong potency after isolation calls for attentions to the 
niche suppression of ASC behavior, especially by neighboring EC. Indeed, it has 
been noted that adipogenic differentiation of ASC is inhibited by EC so that more 
ASC can be preserved to stabilize vasculature.101 It remains unknown how EC 
affects anti-inflammatory functions of ASC.  
Tumor necrosis factor-induced glycoprotein 6 (TSG-6) was first discovered 
in TNFα-treated fibroblasts.33 TSG-6 expression has been observed in 
physiological and pathological contexts associated with inflammation and tissue 
remodeling, for example in the synovial fluid of arthritis patients and serum of 
lupus patients.49, 50 Local or systemic injection of TSG-6 has been proven to 
effectively attenuate inflammation in a diversity of disease models, including 
arthritis, myocardial infarction, corneal injury, acute lung injury, and peritonitis, to 
name a few.47, 54, 55, 58 Histology of affected tissue in these models consistently 
showed significantly reduced infiltration of leukocytes as a result of TSG-6 
injection. Reported mechanisms of TSG-6 include: 1) it inhibits the inflammatory 
network of proteases primarily by increasing the inhibitory activity of inter-a-
inhibitor; 2) it binds to fragments of hyaluronan and thereby blunts their 
proinflammatory effects; 3) it inhibits TNFα secretion from macrophages. How 
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TSG-6 affects endothelial permeability and lymphocyte proliferation, two critical 
steps in the inflammatory cascade, remains unknown.  
We aimed to address these questions by constructing in vitro models to 
study interactions between ASC and vascular EC in the context of inflammation. 
We also looked into the effect of TSG-6, a critical anti-inflammatory cytokine that 
has previously not been noticed in the secretome of ASC, in these models to 
better understand its mechanism of mitigating inflammation. 
 
2.2 Materials and Methods 
Cell culture 
Human ASC were isolated from human subcutaneous adipose tissue 
samples obtained from liposuction procedures, as previously described.102 
Briefly, samples were digested in collagenase Type I solution (Worthington 
Biochemical) under agitation for 1 hr at 37°C, and centrifuged at 300 g for 8 min 
to separate the stromal cell fraction (pellet) from adipocytes. The pellets were 
filtered through 250 µm Nitex filters (Sefar America Inc.) and treated with red cell 
lysis buffer (154 mM NH4Cl, 10 mM KHCO3, and 0.1 mM ethylenediamine-
tetraacetic acid). The final pellet was resuspended and cultured in EGM-2MV 
growth media (Lonza). ASC were passaged when 60–80% confluent and used at 
passages three to five.  
Human umbilical vein endothelial cells (HUVEC) were purchased from 
Lonza and cultured in EGM-2 media per manufacturer’s instruction. Passage 8-
10 HUVEC were used for this study. For co-culture, ASC at 6 X 104 cells/cm2 and 
HUVEC at 5-10 X 103 cells/cm2 were premixed before plating and then cultured 
in EBM-2/5% fetal bovine serum (FBS) for 6-8 days with medium change every 3 
days. To compare TSG-6 secretion profile, ASC cultured alone or co-cultured 
with EC were washed with phosphate buffer saline (PBS, Gibco) on day 7 and 
treated with 20 ng/ml human TNFα (R&D systems) in fresh EBM-2 medium. After 
24 hrs, culture supernatant was collected and concentrated by 8-10 fold using 10 
kD Amicon Ultra centrifugal filter (Millipore) for analysis of TSG-6 levels. 
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Western Blot for human TSG-6 
To measure the secretion of human TSG-6 protein, Western blot analysis 
was performed. Concentrated culture media samples were separated by 
electrophoresis on 10% Precise Protein Gels (Thermo Scientific) under 
denaturing and reducing conditions. Proteins in gels were transferred to a 
nitrocellulose membrane, which was then blocked with 5% (wt./vol.) fat-free milk 
in PBST (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% [vol./vol.] Tween-20), 
followed by sequential incubation with human TSG-6 affinity purified goat IgG 
(R&D systems, 1:200), and Donkey anti-goat secondary antibody (Santa Cruz, 
1:5000), using nonspecific Naphthol blue black (Sigma) staining as the loading 
control. Immunoreactive proteins were detected with SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific). 
 
PMN and Lymphocyte Isolation 
Polymorphonuclear cells (PMN) and lymphocytes were isolated from 
peripheral blood using Ficoll-Paque Plus (GE Healthcare Life Sciences) 
according to manufacturer’s instructions. Briefly, 30 ml peripheral venous blood 
from healthy human donors was centrifuged at 900 g for 10 min. The plasma was 
removed, and the leukocyte-rich upper layer was transferred to a new tube and 
diluted to 30 ml with Hank’s Balanced Salt Solution (HBSS, Thermo Scientific). 
The cell suspension was then layered onto 15 ml Ficoll-Paque Plus (GE 
Healthcare Life Sciences). After centrifugation at 400 g for 40 min, the sample 
was divided into layers of (from top to bottom) plasma, lymphocytes, Ficoll-Paque 
Plus, PMN, and erythrocytes. Lymphocytes and PMN were collected from 
corresponding layers, incubated in erythrocyte lysis buffer for 10 min and washed 
twice with HBSS before immediate use. 
 
FITC-bovine serum albumin (BSA) Permeability Assay 
We performed permeability assays across HUVEC monolayers using a 
Transwell system (Figure 3) as previously described.103 Transwell permeable 
supports (Corning) with polycarbonate membranes (6.5 mm in diameter, 3 µm 
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pore size and pore density of 108/cm2) were coated with Matrigel (BD 
Biosciences) for 1 hr at 37°C. The membranes were seeded with HUVEC 
growing in EGM-2 media until they formed a complete monolayer. The integrity of 
confluent EC monolayer was assessed by Alexa Fluor® 488 Phalloidin 
(Invitrogen) staining and by including a non-treated control in each experiment. 
To induce permeability, human thrombin (10-50 U/ml, Sigma) together with 100 
µg/ml FITC-BSA (Sigma) was added to the lower compartment. At different time 
points after treatment, 10 µl of media from the upper compartment were sampled 
and diluted in 90 µl water/well in a 96-well plate. Fluorescent intensity was 
measured on a fluorometer (SpectraMax M5; Molecular Devices) with excitation 
at 485 nm and emission at 535 nm. 
 
PMN Transmigration through HUVEC Monolayer 
Transwell inserts were coated with HUVEC monolayer in the same way as 
for the FITC-BSA permeability assays. For thrombin-induced transmigration 
assay, EC monolayer was serum-starved for 2 hrs before adding 2 X 106 PMN in 
the volume of 100 µl to the upper chamber and thrombin (10 U/ml, Sigma), D-
Phenylalanyl-L-Prolyl-L-Arginine Chloromethyl Ketone (PPACK, thrombin 
inhibitor, 0.1 µM, Millipore), or TSG-6 (100 ng/ml, R&D systems) were added to 
the lower compartment. For ASC treatment groups, the lower compartment has 
been coated with confluent human ASC one day before the experiment. After 4-6 
hrs, cells that had migrated into the lower compartment were collected, stained 
with FITC-CD11b Ab (BD Biosciences), and counted on flow cytometer (Guava 
EasyCyte 8HT, Millipore).  
For TNFα-induced transmigration assay, PMN were labeled green using 
CellTrace™ CFSE (Invitrogen) before loading to the upper chamber. After serum 
starvation of EC monolayer for 3 hrs and incubation with human TNFα (20 ng/ml) 
for 3 hrs, inserts were removed and cells migrated into the lower compartment 
were counted under fluorescent microscope (Eclipse Ti, Nikon). 
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Figure 3. Polymorphonuclear cell (PMN) transmigration assay.  
A lateral view of the Transwell system is shown. Human umbilical vein 
endothelial cells (HUVEC) were seeded until confluent in Matrigel-coated 
transwell inserts (3 µm pore size and a surface area of 0.33 cm2). Human 
adipose stem cells (hASC) were seeded in the lower compartment without inserts 
on top at first. HUVEC monolayer was serum-starved for 2 hrs and incubated 
with PPACK (thrombin inhibitor), TSG-6, or hASC for 30 min before treatment of 
thrombin or TNFα. There was no physical contact between HUVEC and hASC. 
Permeability of endothelial monolayer to PMN was assessed by adding PMN 
only to the upper compartment and measuring their unidirectional flux to the 
lower compartment. There was no hydrostatic pressure gradient between 
compartments.  
 
  
	   21 
Lymphocyte Proliferation Assay 
The mononuclear cell (MNC) fraction was stimulated with mouse anti-
human CD3 (1 µg/ml; BD Biosciences) and mouse anti-human CD28 (0.5 µg/ml; 
BD Biosciences). Cell cultures were then incubated for 6 days at 37°C / 5% CO2. 
Eighteen hours before the end of the experiment, 3H-thymidine (0-5 mCi/well) 
was added to each of the wells. On day 7, cell proliferation was determined by 
measuring the incorporation of 3H-thymidine using a β-plate reader and 
quantified as counts per minute (cpm).  
 
Statistical Analyses 
Data are shown as mean ± standard error (SEM). Comparisons between 
two groups were made with the use of analysis of variance (ANOVA) and 
Newman-Keuls post-hoc analysis. A p value of < 0.05 was considered significant. 
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2.3 Results 
Niche Endothelial Cells Inhibit Secretion of TSG-6 from ASC  
Previous studies have shown that ASC reside in perivascular niche, in the 
neighborhood of endothelial cells (EC).32 To simulate their in vivo niche 
environment, we cultured ASC with EC for 7 days. EC (positively stained with 
FITC-CD31) distributed randomly on plates in early days (day 2) but gradually 
anastomosed with each other and aggregated to form cord-like structures, much 
resembling their behavior as vascular blocks during neovascularization (Figure 
4A). This was accompanied by migration of ASC to surround these cord-like 
structures. Interestingly, in this peri-endothelial cell niche, the secretion of TSG-6 
from ASC induced by TNFα was significantly suppressed compared to that from 
ASC cultured alone (Figure 4B). The suppressive effect of EC on ASC suggests 
that EC play an important regulatory role in the quiescence of ASC located in 
peri-vascular niche; and that prominent therapeutic effects observed in isolated 
ASC may be partly due to enhanced secretions of TSG-6 after ASC were 
liberated from suppression by EC. 
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Figure 4. Niche endothelial cells suppress TSG-6 secretion from ASC.  
(A) Cord-like structures were formed by migrated endothelial cells and 
surrounded by ASC after co-culture for 8 days. (B) Neighboring endothelial cells 
(HUVEC), which do not produce TSG-6 by themselves, suppressed TNFα-
induced secretion of TSG-6 from ASC. Blots are representative of 3 independent 
experiments. 
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Effects of ASC and TSG-6 on thrombin-induced hyperpermeability to Albumin 
To determine the reciprocal effect of ASC on EC and the role of TSG-6, 
we next looked into effects of ASC and TSG6 on endothelial barrier function. 
Vascular leakage to proteins such as albumin is the major cause of edema in 
inflammation. We used an EC monolayer on Matrigel-coated transwell inserts to 
mimic the intact vascular wall barrier. We also used thrombin, which is activated 
from prothrombin on the surface of endothelial cells when inflammation occurs, 
as an inducer of hyperpermeability as described previously.104 We chose the 
dose of 10 U/ml for all experiments in this study because a lower dose tested (1 
U/ml) was not sufficient to induce leaking of EC monolayer (Figure 5A). 
Treatment with 10 U/ml human thrombin resulted in an acute progressive leaking 
of FITC-BSA across the endothelial monolayer, which cannot be further 
augmented with higher dose (Figure 5B). The permeability to albumin induced by 
thrombin was decreased by thrombin inhibitor PPACK and equally by human 
ASC without contact with EC, but not by 100 ng/ml (higher than baseline 
secretion level in ASC supernatant) TSG-6. This protective effect became more 
prominent after prolonged treatment (from 4 to 72 hrs) of thrombin (Figure 5B). 
These results indicate that TSG-6 alone could not substitute the inhibitory effect 
of ASC on thrombin-induced leaking of albumin; and there may be other factors 
in the ASC secretome that contribute to the protection of endothelial barrier.  
	   25 
 
Figure 5. Effects of ASC and TSG-6 on permeability of EC monolayer to 
FITC-bovine serum albumin (BSA).  
Permeability across EC monolayer was determined by measuring intensity of 
fluorescence (relative fluorescent unit) in the upper compartment (FITC-BSA was 
added to the lower compartment). (A) Permeability to FITC-BSA began to 
increase, compared to non-treated control, approximately 1 hr after thrombin 
treatment. Strongest induction was achieved with 10 U/ml thrombin. (B) ASC 
significantly reduced thrombin-induced EC permeability to the level of non-
treated control and thrombin inhibitor (PPACK) groups. Inhibitory effects of 
PPACK and ASC on EC permeability became more obvious with prolonged 
treatment time (24 hrs and 72hrs). Such effect was not observed in the TSG-6 
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group. Data shown are mean ± SEM in one representative experiment. ap<0.05 
(vs. non-treated control, NC); bp<0.05 (vs. vehicle). 
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Effects of ASC and TSG-6 on thrombin-induced PMN Transmigration 
Compared to leaking of albumin, extravasation of neutrophils across 
endothelium is governed by distinct mechanisms involving adhesion molecules 
and junctional proteins on endothelial cells. Thrombin induces leukocyte 
extravasation by 1) enhancing chemotaxis of leukocyte; 2) promoting adhesion of 
leukocyte to endothelium; and 3) dissociating intercellular junctions between 
endothelial cells.104 We observed minimum transmigration of PMN in the non-
treated group, which confirmed the integrity of a confluent EC monolayer. 
Treatment with 10 U/ml human thrombin elicited vast PMN transmigration across 
the monolayer, which was abrogated when thrombin was neutralized by its 
inhibitor PPACK. Co-cultured hASC in the lower compartment, without physical 
contact with EC, also reduced the migration of PMN, to the same effect as 
PPACK. TSG-6 protein (100 ng/ml) did not stop the leaking of FITC-BSA, but it 
did inhibit PMN transmigration across endothelial monolayer, although the effect 
was weaker than that of ASC (Figure 6).  
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Figure 6. Thrombin-induced PMN transmigration across EC monolayer and 
modulatory effects of ASC and TSG-6.  
Migrated PMN were floating in the lower compartment (white dots) while human 
ASC (ASC group) were attached to the bottom (spindle shaped). Integrity of EC 
monolayer was confirmed by minimum migration of PMN to the lower 
compartment (non-treated group) and absence of intercellular gaps upon Alexa 
Fluor® 488 phalloidin staining of actin (green).  
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To quantify migrated PMN in the lower compartment without interference 
from co-existing hASC, all cells in the lower compartment were trypsinized, 
collected, stained with CD11b Ab, and counted on flow cytometry. The accuracy 
of this method is justified by the linear standard curve showing positive 
correlation between events on flow cytometry and the number of PMN (counted 
by hemocytometer) in each sample (Figure 7). In accordance with microscopic 
findings, PPACK, hASC and TSG-6 reduced the transmigration rate of PMN from 
3.8 ± 0.6% to 0.2 ± 0.02%, 0.1 ± 0.02% and 2.0 ± 0.5%, respectively (Figure 8B). 
Since ASC were not in direct contact with EC on inserts, the potent inhibitory 
effect of ASC was most likely attributed to cell-secreted trophic factors, such as 
TSG-6. This speculation motivated our further efforts to look into the efficacy of 
ASC conditioned media. 
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Figure 7. Quantification of thrombin-induced PMN trans-endothelial 
migration by flow cytometry.  
(A) Flow cytometry allows for distinction between migrated PMN and ASC in the 
lower compartment. (B) Live PMN (Calcein AM+ CD11b+) were counted for each 
sample. (C) PMN stained with IgG isotype Ab were CalceinAM+ CD11b-. (D) 
PMN stained with CD11b Ab but killed by methanol were CalceinAM- CD11b+. 
(E) The flow cytometry-based counting of viable PMN is proportional to the 
number of PMN (counted by hemocytometer) in each sample.  
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Effects of ASC conditioned media on thrombin-induced PMN Transmigration 
If ASC do function through certain trophic factors, such as TSG-6, 
conditioned media from ASC should yield equivalent effects. The challenge is 
that it is difficult to calibrate the condition media to precisely recapitulate activities 
of ASC because ASC might be affected remotely by the presence of other cell 
populations in the model, such as EC and PMN or other stimulatory signals such 
as thrombin. To take into account possible influences from these environmental 
factors, we generated conditioned media from several different culture conditions, 
including 1) hASC only; 2) hASC (in lower compartment) + EC (on inserts); 3) 
hASC + EC + PMN (in upper compartment); 4) hASC + thrombin; 5) hASC + EC 
+ thrombin; 6) hASC + EC + PMN + thrombin (Figure 8A). These conditioned 
media were used to replace assay media for the next PMN transmigration assay 
for efficacy evaluation. Surprisingly, thrombin in conditioned media from ASC 
alone or ASC + EC induced higher permeability than in regular assay media, 
whereas thrombin in conditioned media from ASC + EC + PMN induced the 
same level of permeability as in regular assay media (Figure 8C). Moreover, 
adding thrombin to the conditioned media generation process also failed to 
induce any anti-permeability effect of the conditioned media (Figure 8D). These 
results showed that, at least in this assay, the presence of ASC is indispensible 
to maintain their barrier-protective effect. 
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Figure 8. Effects of ASC, ASC conditioned media, and TSG-6 on thrombin-
induced PMN transmigration.  
(A) Conditioned media was harvested from ASC, ASC + EC, or ASC + EC + 
PMN, incubated with (CMAT, CMAET, CMAEPT, respectively) or without (CMA, 
CMAE, CMAEP, respectively) 10 U/ml thrombin for 6 hrs and frozen until use. (B) 
ASC completely abrogated thrombin-induced PMN transmigration, comparable to 
PPACK (PPK). TSG-6 significantly reduced the permeability, but less effectively 
than ASC. (C) Conditioned media from ASC (CMA) or ASC + EC culture (CMAE) 
in the absence of thrombin increased PMN transmigration, whereas conditioned 
media from ASC + EC + PMN (CMAEP) had no effect. (D) Conditioned media from 
thrombin-stimulated ASC (CMAT), ASC + EC (CMAET), or ASC + EC + PMN 
(CMAEPT) did not show any inhibitory effect either. Mean ± SEM, n=3/group. 
ap<0.05, (vs. non-treated control, NC); bp<0.05, vs. (vehicle). 
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Effects of ASC and TSG-6 on TNFα-induced PMN Transmigration 
The pro-inflammatory cytokine TNFα is another potent inducer of vascular 
permeability during inflammation. In contrast to thrombin, TNFα triggered 
endothelial permeability mainly through microfilament rearrangement, 
microtubule destabilization, and disruption of vascular endothelial (VE)-cadherin-
based intercellular junctions.105-108 Therefore, unlike acute-acting thrombin, TNFα 
increases endothelial permeability progressively within the first 8-10 hrs and 
maintains its effect for more than 24 hrs.109 To investigate effects of hASC and 
TSG-6 against TNFα-induced hyperpermeability, we employed a similar transwell 
model as the one for thrombin, except this time, we pre-labeled PMN with 
fluorescent tracker carboxy fluorescein diacetate succinimidyl ester (CFSE) so 
that they can be counted distinctly from nonfluorescent ASC under fluorescent 
microscope. Similar to our findings in thrombin-induced endothelial permeability, 
both hASC and TSG-6 significantly attenuated PMN transmigration from 4.0 ± 
0.5% to 1.2 ± 0.3% and 0.9 ± 0.3% respectively (Figure 9). The high similarities 
between effects of ASC and TSG-6 in this assay further support a potential role 
of TSG-6 in mediating anti-permeability actions of ASC. To prove this hypothesis, 
it is necessary to knock down TSG-6 and evaluate its influence on anti-
inflammatory activities of ASC, this is addressed in Chapter 3.  
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Figure 9. Transmigration of PMN induced by TNFα and inhibitory effects of 
hASC and TSG-6.  
Human PMN were labeled with CFSE cell tracker (green) before adding to the 
upper compartment. Images were taken from lower compartment after TNFα 
treatment for 3 hrs. Mean ± SEM, n=3/group. ap<0.05 (vs. NC); bp<0.05, (vs. 
vehicle). Images are representative for each condition run in triplicates. 
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ASC, ASC-CM and TSG-6 Suppress Lymphocyte Activation 
The initial tissue damage from neutrophil infiltration is exponentially 
magnified after cytotoxic lymphocytes are activated into proliferation phase.110 To 
investigate the effect of ASC/ASC-CM/TSG-6 on this phase of inflammation, we 
incubated human peripheral blood mononuclear cell (MNC) with anti-CD3 and 
CD28 mAbs, which are known mitogens to stimulate lymphocyte proliferation.111 
Compared to the non-treated control (0.66 ± 0.07 X 103 cpm), stimulation with 
anti-CD3 and CD28 mAbs induced strong proliferative responses of lymphocytes 
(16.9 ± 2.0 X 103 cpm). Co-incubation with human ASC significantly inhibited 
MNC proliferation, in a dose-dependent manner. This inhibitory effect of hASC 
can be fully reproduced by conditioned media from hASC activated with 20 ng/ml 
hTNFα. Intriguingly, despite all other factors secreted from hASC, TSG-6 alone, 
also effectively suppressed lymphocyte activation, suggesting an important role 
of this cytokine in the modulation of lymphocyte proliferation by ASC (Figure 10). 
Therefore, at least in this model, ASC suppressed CD3/CD28 Ab-activated 
lymphocyte proliferation via trophic factors, such as TSG-6.  
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Figure 10. ASC, ASC conditioned media, and TSG-6 attenuate lymphocyte 
proliferation.  
Mononuclear cells (MNC) activated by anti-CD3 and anti-CD28 show a 
significant increase in proliferation compared with inactivated MNC and was 
attenuated by ASC, ASC-conditioned media (ASC-CM) or TSG-6 protein dose-
dependently, as measured by thymidine incorporation. Mean ± SEM, n=4/group. 
ap<0.05 (vs. non-treated control); bp<0.05 (vs. vehicle). 
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2.4 Conclusion 
Our results showed that ASC actively respond to the inflammatory 
signaling of TNFα by strong upregulation and release of the anti-inflammatory 
cytokine TSG-6. This feedback response of ASC was suppressed by neighboring 
niche endothelial cells. We also demonstrated protective effects of ASC on 
thrombin or TNFα induced hyperpermeability of EC monolayer to albumin or 
neutrophils. Moreover, the inducible trophic factor TSG-6 from ASC was able to 
reproduce the inhibitory effect of ASC on thrombin or TNFα-induced neutrophil 
transmigration across EC monolayer but not albumin leaking. TSG-6 as an anti-
inflammatory cytokine newly identified in the ASC secretome was also able to 
dose-dependently abrogate mitogen-induced proliferation of lymphocytes, similar 
to ASC or ASC-conditioned media. These findings highlight the orchestrated 
immunomodulation mediated by TSG-6 when released from ASC upon TNFα 
activation.  
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2.5 Discussion 
To study the permeability of endothelium, we tried to model the in vivo 
situation by using primary human endothelial cells and transwell filter units 
coated with Matrigel, extracellular matrix that mimics basal lamina. In addition to 
commonly used FITC-BSA, we also used migration of neutrophils freshly isolated 
from human peripheral blood as an indicator for the permeability, because 
neutrophil infiltration is a hallmark of early-stage inflammation and has been 
consistently shown to improve after MSC/TSG-6 injection in multiple disease 
models. The challenge with this approach, however, is the complexity of result 
interpretation, since smaller number of migrated neutrophils in the lower 
compartment could be attributed to blocking of inducers (thrombin or TNFα in this 
case), protection of intercellular junctions and cytoskeleton of endothelial cells, 
immobilization of neutrophils, or all in combination. Our data showed that human 
ASC not only reduced leaking of FITC-BSA across EC monolayer but also 
inhibited leukocyte transmigration induced both by thrombin and TNFα. Such 
general effects of hASC highly suggest that endothelial cell junction and 
cytoskeleton, the common ground among these different models, as most likely 
targets of action. Therefore, next-step efforts for addressing intracellular 
mechanism should be focused on junction proteins (i.e. VE-Cadherin), 
endothelial cytoskeletons (i.e. F-actin), as well as their regulatory signaling 
molecules.  
One recent study reported that HUVEC, once cultured with bone marrow 
stem cells (then separated by sorting), demonstrated higher resistance to 
vascular endothelial growth factor A (VEGFA)-induced permeability to dextran 
than those cultured alone.29 In contrast, our model put EC and ASC together in 
the same reaction system without physical contact to allow for continuous 
dynamic crosstalk between these two cell types. Intriguingly, in previous report, 
conditioned media from MSC and EC co-culture but not MSC alone were able to 
reproduce the protective effect of MSC preconditioning on EC. Although our 
results also support the hypothesis that the inhibitory effect of ASC derived from 
paracrine factors not present / active in regular ASC culture media, we did not 
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observe any effect of conditioned media from various cell combinations either. 
One possibility could be that these factors were unstable or consumed so quickly 
that presence of producer cells was indispensible to maintain lasting effects.  
Although reduced neutrophil infiltration subsequent to TSG-6 injection was 
reported in many in vivo studies, the cellular and molecular mechanisms remain 
a mystery. Our data showed a strong antagonistic effect of TSG-6 against TNFα-
induced endothelial hyperpermeability leading to neutrophil extravasation. This 
finding, combined with the fact that TNFα activates the release of TSG-6 from 
hASC, revealed a potential feedback protection mechanism mediated by TSG-6 
in the perivascular niche triggered by inflammatory cytokine TNFα. CD44, a 
receptor for TSG-6, is expressed abundantly in endothelial cells and is the key 
mediator for the protection of hyaluronan and HGF against vascular leakiness.112, 
113 It has been reported to be upregulated by TNFα in endothelial cells to 
facilitate monocyte adhesion and transmigration.114 Given these connections, it 
would be interesting to look into changes of CD44 expression and distribution in 
EC monolayer and determine its relevance to the activities of TSG-6. 
The suppression of TSG-6 secretion from ASC by niche EC is interesting 
but not surprising. After all, there is no need to activate quiescent ASC from the 
niche when vascular wall is intact in the absence of inflammation. However, 
when vascular injury occurs and restraints from EC on ASC are removed, 
secretion of TSG-6 from ASC in response to TNFα serves as a need-based 
protection mechanism to attenuate inflammation by repairing vascular leakiness 
and suppressing lymphocyte activation (Figure 11). In case of severe injury when 
this internal defense mechanism becomes insufficient, harvesting stromal 
vascular fraction to enrich ASC and delivering them into circulation may be a 
necessary therapeutic measure, because it would augment the efficiency of 
TSG-6 production by directly exposing large amounts of ASC to stimulatory 
signals. Notably, based on our results, this procedure may not be simplified into 
conditioned media or cytokine cocktails in certain occasions, because activities of 
ASC may rely on the continuous crosstalk between ASC and nearby cells and 
environmental signals.  
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In this chapter we identified TSG-6 in the secretome of ASC and 
demonstrated its potent anti-inflammatory functions via modulation of endothelial 
barrier and lymphocyte proliferation, similarly to ASC. However, the relative 
contribution of TSG-6 to the anti-inflammatory activities of ASC will be elucidated 
in experiments that investigate ASC effects while TSG-6 secretion is inhibited, 
described in the next chapter. 
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Figure 11. Illustration of cell dynamics in perivascular niche in response to 
inflammation.  
1) ASC quiescently reside in perivascular niche in normal vasculature but can be 
enriched through liposuction and isolation, and administered systemically as a 
therapeutic measure; 2) when vascular injury occurs, TNFα is released from 
immune cells and thrombin is activated from prothrombin, both of which cause 
leaking of vascular wall to albumin and neutrophils (PMN), resulting in edema 
and tissue damage; 3) tissue injury was worsened in later stage when mitogens 
induce excessive proliferation of cytotoxic lymphocytes; 4) once ASC are 
liberated from niche environment, either through vascular injury or more 
effectively and abundantly through cell isolation, and administered systemically, 
they respond to TNFα stimulation by highly increased secretion of TSG-6; 5) 
A B
C
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TSG-6 not only inhibits extravasation of neutrophils but also suppresses mitogen-
induced lymphocyte proliferation. 
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Chapter 3. Quantitation of TSG-6 Secretion from ASC and Investigation of 
TSG-6 Role in Rescuing Hindlimb Ischemia 
3.1 Introduction 
To be able to confidently confirm the knockdown of TSG-6 in ASC, it is 
essential to accurately quantitate the amount of TSG-6 secretion. Although we 
were able to detect cytokine TSG-6 in the culture medium by Western blotting, 
this method became inconvenient to measure large numbers of small-volume 
samples because it requires concentration of supernatant and depletion of 
confounding serum proteins. Besides, for cell culture supernatants, it is difficult to 
find an optimal loading-control protein since products of regular housekeeping 
genes, such as GAPDH and β-actin, are not secreted into supernatant. In order 
to better characterize TSG-6 cytokine in different cell types and body fluid 
specimens, as well as quality control the knockdown of TSG-6 more effectively, 
an effective method of quantification, such as enzyme-linked immunosorbent 
assay (ELISA) for TSG-6 is highly warranted. In 2009, Lee et al published the 
first ELISA protocol for human TSG-6 using antibodies from R&D systems.54 We 
optimized this ELISA protocol and used it to verify TSG-6 knockdown in human 
ASC. Similarly, for measurement of murine TSG-6, we used commercially 
available antibodies from R&D systems and validated our ELISA using samples 
from TSG-6-/- mice-derived murine ASC and comparing our results with those 
obtained using the ELISA developed by Dr. Mickecz.115 
ASC have been shown to attenuate inflammation in multiple disease 
models. Therefore, the next step to study the role of TSG-6 in ASC activities is to 
assess the performance of ASC in such models after TSG-6 is knocked down. 
Inflammation arises when large numbers of host cells die in an ischemic attack, 
such as critical limb ischemia or myocardial infarction. If not properly resolved, it 
may lead to a vicious cycle of aggravated tissue damage accompanied by 
escalating excessive inflammation.2, 3 We have previously established a murine 
hindlimb ischemia model and witnessed enhanced blood flow recovery and 
neovascularization as a result of ASC injection, largely due to potent paracrine 
factors from cells, such as vascular endothelial growth factor (VEGF) and 
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hepatocyte growth factor (HGF).102, 116, 117 In light of the newly identified anti-
inflammatory cytokine TSG-6 in the secretome of ASC, we set out to investigate 
the role of TSG-6 as mediators of the effect of ASC in ameliorating ischemia-
induced tissue damage. We also included blood reperfusion as an endpoint to 
better determine whether TSG-6 may contribute to its improvement either via 
direct angiogenic effect or via limiting tissue damage at an early stage of injury.  
 
3.2 Materials and Methods 
Cell culture 
Inguinal adipose tissues of 8-12 weeks old C57BL/6 mice or C.129S6-
Tnfaip6tm1Cful/J (TSG-6-/-) mice (gifted by Dr. Katalin Mikecz, Rush University) 
were isolated and digested at 37°C in PBS containing 2% bovine serum albumin 
(BSA) and 2 mg/ml collagenase (collagenase A, Roche) for 15-20 min. After 
filtration through 40 µm nylon filter mesh (BD Falcon) and centrifugation, isolated 
cells were suspended in medium, counted with a hemocytometer, plated at 5 X 
104 cells/ml in 75 cm2 tissue culture flasks, and cultured at the presence of 
EGM2MV medium (Lonza) supplemented with 10% FBS. The cells were daily 
observed under an inverted phase-contrast microscope and were passaged after 
70-80% confluence. The culture media was changed every two days. 
 
Animals 
For experiments evaluating limb necrosis as primary endpoints, BALB/c 
mice (8-10 weeks old, mixed-gender, Jackson Labs) were used because this 
strain is most susceptible to limb necrosis after femoral artery ligation (FAL).118 
To test the efficacy of murine ASC and involvement of TSG-6, 24 hrs after FAL, 
vehicle (PBS) or 2.5 X 105 murine ASC from wild type C57BL/6 or TSG-6-/- mice 
were administered through bolus intramuscular injections at 2 sites in 
gastrocnemius muscle of the ischemic leg. To determine the efficacy of human 
ASC and involvement of TSG-6, 2 hrs after FAL, vehicle or 5 X 105 human ASC 
not transfected, transfected with TSG-6 siRNA, or with scramble control were 
administered through intravenous bolus injection. For experiments evaluating 
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limb distal vascular perfusion as endpoints, NOD.Cg-Prkdcscid IL2rgtmlwjl/SZJ 
(NSG) mice (8-10 weeks old, female, Indiana University Simon Cancer Center) 
were used because their rate of blood reperfusion after FAL was less variable. 
On post-surgical day 1, vehicle or 1 X 106 human ASC not transfected, 
transfected with TSG-6 siRNA, or with scramble control were administered 
through intravenous bolus injection. Mice were housed in an environmentally 
controlled room and were fed chow and water ad libitum. The care of mice 
complied with the National Research Council’s Guide for the Care and Use of 
Laboratory Animals. All protocols were approved in accordance with the 
Committee on Animal Research at Indiana University. 
 
ELISA for Human TSG-6 
TSG-6 protein levels in medium from hTNFα-treated hASC were 
determined by ELISA as previously described with modifications.54 A 96-well 
plate (Maxisorp; Nunc) was coated overnight at 4°C with 50 µl of 10 µg/ml 
monoclonal antibody specific for TSG-6 (clone A38.1.20; Santa Cruz 
Biotechnology, Inc.) in 0.2 M sodium bicarbonate buffer (pH 9.2). Plates were 
washed with PBS after this and all subsequent steps. Nonspecific sites were 
blocked with 0.25% (w/v) BSA in PBS/0.05% (v/v) Tween (blocking buffer) for 1 
hr at room temperature. Samples of 50 µl or standards of recombinant human 
TSG-6 protein (R&D Systems) in dilution buffer were added and incubated for 2 
hrs at room temperature, followed by 50 µl/well of 0.5 µg/ml biotinylated anti-
human TSG-6 (R&D Systems) in blocking buffer for 2 hrs at room temperature. 
Bound antibody was detected by incubation for 20 min with streptavidin-
horseradish peroxidase (HRP) (R&D Systems), diluted 1: 200 in PBS and then 
with substrate solution (R&D Systems) for 20 min. Absorbance at 450 nm and 
584 nm was measured by spectrophotometer (SpectraMax M5; Molecular 
Devices). 
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ELISA for Murine TSG-6 (ELISA_X) 
This ELISA was newly developed using combinations of commercially 
available antibodies. A 96-well plate (Maxisorp; Nunc) was coated overnight at 
room temperature with 50 µl of 10 µg/ml monoclonal antibody specific for TSG-6 
(clone A38.1.20; Santa Cruz Biotechnology, Inc.) in 0.2 M sodium bicarbonate 
buffer (pH 9.2). Plates were washed with PBS after this and all subsequent 
steps. Nonspecific sites were blocked with 0.25% (w/v) BSA in PBS/0.05% (v/v) 
Tween (blocking buffer) for 2 hrs at room temperature. Samples of 50 µl or 
standards of recombinant murine TSG-6 protein (R&D Systems) in dilution buffer 
were added and incubated for 2 hrs at room temperature, followed by 50 µl/well 
of 0.5 µg/ml biotinylated anti-mouse TSG-6 (R&D Systems) in blocking buffer for 
2 hrs at room temperature. Bound antibody was detected by incubation for 20 
min with streptavidin-HRP (R&D Systems), diluted 1: 200 in PBS and then with 
substrate solution (R&D Systems) for 20 min. Absorbance at 450 nm and 584 nm 
was measured by spectrophotometer (SpectraMax M5; Molecular Devices). 
 
Alternative ELISA for Murine TSG-6 (ELISA_M) 
This ELISA was developed by Dr. Katalin Mikecz in Rush University 
described in more detail in a recent publication.115 Briefly, a 96-well plate 
(Maxisorp; Nunc) was coated overnight at room temperature with 50 µl of 5 µg/ml 
NG3 antibody (gifted by Dr. Mikecz) in 0.2 M sodium bicarbonate buffer (pH 9.2). 
Plates were washed with PBS after this and all subsequent steps. Nonspecific 
sites were blocked with 1% (w/v) BSA in PBS (blocking buffer) for 2 hrs at room 
temperature. Samples of 50 µl or standards of recombinant murine TSG-6 
protein (gifted by Dr. Mikecz) in dilution buffer (PBS/1%BSA/0.05%NaN3) were 
added and incubated for 2 hrs at room temperature, followed by 50 µl/well of 0.5 
µg/ml biotinylated NG8 antibody (gifted by Dr. Mikecz) in blocking buffer for 2 hrs 
at room temperature. Bound antibody was detected by incubation for 20 min with 
streptavidin-HRP (R&D Systems), diluted 1: 200 in PBS and then with substrate 
solution (R&D Systems) for 20 min. Absorbance at 450 nm and 584 nm was 
measured by spectrophotometer (SpectraMax M5; Molecular Devices). 
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Transfection of Human ASC with TSG-6 siRNA 
A frozen vial of 1.0 X 106 passage 2 hASC was thawed, and plated at 200 
cells/cm2 in 150 mm flasks with 30 ml growth medium (EGM2MV; Lonza) lacking 
antibiotics. Once 40% confluent, cells were transfected with siRNA for TSG-6 
(Santa Cruz Biotechnology) or scramble control (Control siRNA-A; Santa Cruz 
Biotechnology) with a commercial kit (Lipofectamine RNAiMAX reagent; 
Invitrogen). For each 150 mm flask, a mixture of 36 µl siRNA (10 µM), 45 µl 
RNAiMAX, and 3 ml transfection medium (OptiMEM I Medium; Invitrogen) was 
incubated for 20 min at room temperature and then diluted by 10 fold with 
OptiMEM I medium before adding to the cells. After incubation for 6 hrs, the 
medium was replaced with 30 ml growth medium (EGM2MV). To confirm 
knockdown of TSG-6, mRNA and protein of TSG-6 were assayed by real-time 
PCR and ELISA respectively. 
 
Mouse hindlimb ischemia model 
Left femoral artery excision was performed as described previously.116 
Briefly, mice were anesthetized using 2% isoflurane inhalation, delivered under a 
constant oxygen flow rate of 1 L/min. A 0.5-1 cm skin incision was made 
longitudinally on the anterior thigh of the left hind limb. The femoral artery was 
exposed under a surgical microscope and dissected from the femoral vein and 
nerve. The femoral artery and visible branches were ligated proximal to the 
superficial epigastric artery and above the bifurcation of the saphenous and 
popliteal arteries with 5.0 silk ligatures. The arterial segment between the 
ligatures was excised (Figure 12A). Incision was closed with a 5.0 polypropylene 
suture. Mice received 0.05-0.1 mg/kg subcutaneous Buprenorphine HCL for pain 
relief. Hind limb blood flow was assessed immediately before and after ligation 
using Laser Doppler Imaging (Figure 12B and C). 
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Figure 12. Murine hindlimb ischemia model. 
(A) Left femoral artery was ligated and excised between the proximal and distal 
ligations. Cited from JOV (http://www.biolab.cn/plus/view-428230-1.html). (B) To 
measure blood perfusion to the limb, mice were anaesthetized with both limbs 
resting on a warm pad (37°C). Blood perfusion was quantified by triplicate 
Doppler measurements and normalized to the signal from the contralateral 
normal limb. 
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Limb Necrosis Score 
An eight-point scoring system modified from previous description was 
used to characterize severity of limb necrosis after femoral artery ligation (FAL): 
0 = normal foot color; 1 = foot discoloration, no necrosis; 2 = necrosis of <3 digit 
nails; 3 = necrosis of 3-5 digit nails; 4 = necrosis of <3 digits; 5 = necrosis of 3-5 
digits, foot looks normal; 6 = <40% foot necrosis; 7 = 41-80% foot necrosis; 8 = 
complete foot necrosis. Schematic and representative images were shown in 
Figure 13. 
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Figure 13. Schematic and representative images of limb necrosis scores.  
(A) Schematic showing definition of limb necrosis scores from 0 to 8. 0: normal 
foot color; 1: foot discoloration, no necrosis; 2: necrosis of <3 digit nails; 3: 
necrosis of 3-5 digit nails; 4: necrosis of <3 digits; 5: necrosis of 3-5 digits, foot 
looks normal; 6: <40% foot necrosis; 7: 41-80% foot necrosis; 8: complete foot 
necrosis. (B) Representative images of different scores from this study.  
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Laser Doppler perfusion imaging 
Mice were anesthetized using 1.5% isoflurane anesthesia by facemask, 
delivered under a constant oxygen flow rate of 1 L/min. A Laser Doppler 
perfusion imager (Moor Instruments Ltd) was used to measure dermal blood flow 
in the dorsal calf and footpad on postoperative days 7, 14, 21, 28, 42, 49. 
Perfusion ratios of the operated over contralateral non-operated hindlimb 
(averaged over 3 scans) were compared to minimize differences between 
ambient temperature and lighting. Mice were maintained between 36.8° and 
37.2°C during scanning with a homeothermic warming pad. Image analysis 
software (Laser Doppler Perfusion Measure, V3.08, Moor Instruments) was used 
to calculate the limb mean flux units, which represents a quantitative analysis of 
tissue perfusion on a scale of 0 to 1000. Limb perfusion was expressed as the 
ratio of the Flux value of the ischemic limb relative to the value of the 
contralateral limb (Flux Ratio). 
 
Statistical Analyses 
Data are shown as mean ± SEM. Comparisons between two groups were 
made with the use of ANOVA and Newman-Keuls post-hoc analysis. A p-value < 
0.05 was considered significant. 
 
3.3 Results 
ELISA for human TSG-6 
The only hTSG-6 ELISA based on commercially available antibodies is the 
one published by Lee et al in 2009.54 According to the standard curve in their 
protocol, the ELISA should be sensitive enough to detect < 0.1 ng/ml rhTSG-6 
(Figure 14A). We followed the protocol but found the background noise was so 
strong at low dose range that the minimum detection dose was as high as 16.2 
ng/ml (Figure 14B). Based on the shape of the curve, we chose 62.5-500 ng/ml 
as the optimal range for the linear standard curve in our later ELISA for human 
TSG-6. This ELISA was also specific enough to distinguish human and murine 
TSG-6 even at lowest detectable dose (Figure 14C). One potential pitfall with this 
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ELISA, however, is that it can be interfered easily by serum proteins through 
nonspecific competitive binding (Figure 14D). Therefore, for in vitro cell culture 
samples, as long as samples (such as culture medium) were harvested in serum-
free conditions, detection of human TSG-6 protein would not be affected.  
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Figure 14. ELISA for human TSG-6 protein. 
(A) Standard curve generated by Prockop lab; (B) Using recombinant hTSG-6 
protein from R&D systems, the minimum detection dose (MDD) of hTSG-6 ELISA 
was 16.2 ng/ml. The optimal detection range was 50-500 ng/ml. (C) The ELISA 
was highly specific for human TSG-6 protein with minimum reactivity to murine 
TSG-6. (D) Serum proteins strongly interfered with the detection of human TSG-
6. 
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Comparison of two different ELISAs for murine TSG-6 
In order to quantify murine TSG-6 protein, we developed a new ELISA 
(ELISA_X) using antibodies purchased from R&D systems. Similar to human 
TSG-6 ELISA, we also observed significant interference from bovine serum 
proteins even at concentration of 5% (Figure 15A). We also compared this ELISA 
to an ELISA developed and newly published (in 2012) by Dr. Katalin Mikecz 
(ELISA_M).115 Both methods demonstrated satisfactory linear standard curves 
(R2=0.991 vs. 0.982) at the dose range of 0.3-20 ng/ml (Figure 15B), however, 
ELISA_M showed a higher sensitivity to increased doses of mTSG-6, implying 
higher binding capacity of the antibody to mTSG-6 protein. Notably, only 10% 
dose of mTSG-6 from Mikecz lab was needed to achieve the same intensity of 
absorbance (OD value) as mTSG-6 from R&D (Figure 15B vs. 14A). Such 
difference in activities of standard recombinant proteins from different suppliers 
would result in different quantity readings of the same sample in later 
experiments. 
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Figure 15. ELISA for murine TSG-6 protein.  
(A) Absense of serum proteins in dilution buffer is advisable since serum proteins 
interfere with the detection of murine TSG-6 protein. (B) Standard curves of two 
different ELISAs for murine TSG-6 protein. Antibodies for ELISA_X were 
purchased from R&D systems; antibodies for ELISA_M were a kind gift of Dr. 
Mikcez. 
  
0.0 0.2 0.4 0.6 0.8 1.0 1 2 3 4 5
0
1
2
3
4
EBM2 EBM2/5%FBS
rmTSG6 (ug/ml)
O
D
45
0-
O
D
58
4
A
B
0 5 10 15 20
0.0
0.5
1.0
1.5
2.0
ELISA_X ELISA_M
y = 0.0887x + 0.0575
R! = 0.99115
y = 0.0443x + 0.0971
R! = 0.98159
rmTSG6 (ng/ml)
O
D
45
0-
O
D
58
4
	   57 
Knocking down TSG-6 in human ASC by siRNA 
We have shown in Chapter 2 that inflammatory cytokine TNFα highly 
upregulates secretion of TSG-6 from human ASC. To understand the importance 
of this response mechanism to activities of ASC, it is necessary to mute the 
activation of TSG-6 transcription. For this purpose, human ASC were transfected 
with TSG-6 siRNA. In parallel plates, cells were incubated with Alexa Fluor 555-
labeled dsRNA to verify the efficiency of transfection. After transfection, red 
fluorescence was found in ~90% of cell nuclei. Correspondingly, expression of 
TSG-6 mRNA and secretion of TSG-6 protein in the presence of TNFα 
stimulation both decreased by more than 90% (Figure 16B and C). Although 
scramble control RNA slightly decreased TSG-6 expression, at protein level, it is 
not different from un-transfected control (Figure 16B and C). By washing the cells 
with PBS and incubating for additional 24 hrs with fresh basal medium (EBM2, 
Lonza), we also demonstrated that the memory of stimulation by TNFα and 
interference by TSG-6 siRNA remained in hASC for at least 24 hrs after removal 
of the original treatment (Figure 16D). This allowed us to generate conditioned 
media from regular and inactivated (TSG-6 siRNA transfected) hASC, and 
compare their efficacy without being confounded by TNFα and siRNA.  
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Figure 16. Knockdown of TSG-6 production from human ASC by siRNA.  
(A) Human ASC maintained their normal morphology while more than 90% of 
nuclei had been infiltrated by fluorescently labeled (red) dsRNA. (B & C) Real-
time PCR and ELISA confirmed effective knockdown of TSG-6 at both mRNA 
and protein level. (D) To generate conditioned medium enriched for TSG-6, 
transfected ASC were stimulated with 20 ng/ml human TNFα for 24 hrs, washed 
with PBS twice (to remove TNFα), and incubated in fresh EBM2 medium for 
another 24 hrs before supernatants were harvested. Levels of TSG-6 were 
confirmed by ELISA. N=3/group. **p<0.01. 
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Verification of TSG-6 knockout from murine ASC 
Deficiency of TSG-6 protein causes infertility in female mice and higher 
susceptibility to tissue damage from inflammatory diseases such as arthritis.119 
How absence of TSG-6 gene affects fat tissue and cells derived from it remains 
unknown. To obtain murine ASC with defect in TSG-6 secretion, we harvested 
peri-renal and subinguinal fat tissue from wild type C57BL/6 mice and TSG-6-/- 
mice. The yield and morphology of ASC were similar between two groups of mice 
(Figure 17A and B). To verify functional knockout of TSG-6 gene, murine ASC 
were stimulated with 20 ng/ml murine TNFα for 24 hrs. Murine TSG-6 in the 
supernatant was quantified by two different ELISA methods. Both assays showed 
lower levels of TSG-6 secretion from mASCko compared to mASCwt. Larger 
difference was seen in ELISA_M (Figure 17 C and D). Interestingly, despite a 
similarly strong induction of TSG-6 expression at mRNA level (Figure 17E), the 
productivity of TSG-6 protein was much lower in murine ASC than in human ASC 
(pg vs. ng).  
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Figure 17. Murine ASC from wild type (mASCwt) and TSG-6-/- mice (mASCko). 
No morphological difference was observed between adipose stem cells (ASC) 
isolated from wild type (A) and TSG-6-/- mice (B). Based on both ELISA_M (C) 
and ELISA_X (D), secretion of mTSG-6 from mASCko was lower than from 
mASCwt at baseline and upon murine TNFα (20 ng/ml) stimulation. (E) 
Transcription of TSG-6 in wild type murine ASC was highly upregulated after 24 
hrs of TNFα (20 ng/ml) treatment. 
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Effects of murine ASC on limb necrosis and muscle atrophy 
Ischemic limb necrosis is a typical in vivo inflammation model to assess 
the anti-inflammatory activities of ASC because the tissue damage largely results 
from the release of proteases subsequent to excessive inflammation. Symptoms 
of limb necrosis in BALB/c mice progressed acutely after femoral artery ligation 
and mostly stopped within the first week. We injected murine ASC 
intramuscularly 24 hrs after surgery, because a similar population of 
mesenchymal stem cells, murine marrow stromal cells (BMSC) administered in 
the same time frame through the same route resulted in significant improvement 
of limb necrosis in the same strain of mice.120 Unexpectedly, murine ASC from 
wild type mice failed to improve limb necrosis, although fewer cells were injected 
compared to the previous study (2.5 vs. 10 X 105) due to limited supply. 
Interestingly, ASC from TSG-6-/- mice seemed to further aggravate the symptoms 
(Figure 18A). We also observed large variations in the severity of necrosis 
(scores from 1 to 6) even within the same treatment group, as reflected by the 
large standard deviations (Figure 18B). Overall, no statistical difference was 
observed among all treatment groups. In accordance with the result of necrosis 
scores, calf muscle atrophy also varies among individuals in each group (Figure 
19B). Neither was any significant difference observed.  
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Figure 18. Effects of murine ASC on limb necrosis.  
(A) Progression of limb necrosis after surgery. One day after surgery, BALB/c 
mice were injected locally with 2.5 X 105 mASCwt or mASCko. Severity of necrosis 
was rated from 0 to 8 (lowest to highest), as described in Figure 13. (B) Individual 
variability was observed in all treatment groups. No statistically significant 
difference was observed among groups. PBS = phosphate buffered saline; 
mASCwt / mASCko = murine ASC from wild type or TSG-6-/- mice. Mean ± SEM, 
n=7/group. NS=non significant.  
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Figure 19. Effects of murine ASC on calf muscle atrophy.  
(A) Calf muscle (gastrocnemius and soleus) from both ischemic and contralateral 
normal limbs were excised on post-surgical day 8 and weighed. (B) Severity of 
muscle atrophy was evaluated by calculating the ratio of ischemic vs. normal 
muscle weight. PBS = phosphate buffered saline; mASCwt / mASCko = murine 
ASC from wild type or TSG-6-/- mice. Mean ± SEM, n=7/group. NS=non 
significant.  
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Effects of human ASC on limb necrosis 
We also attempted using human ASC at higher dose (1 X 106/mouse) to 
ameliorate limb necrosis since mesenchymal stem cells from other sources such 
as bone marrow and placenta have demonstrated robust cross-species benefits 
to improve ischemia.54, 121 Besides, according to our above data, human ASC 
secrete more TSG-6 than murine ASC. We also changed the delivery route to 
intravenous injection instead of intramuscular and the time for injection to 2 hrs 
instead of 24 hrs after surgery, because human MSC have been shown to 
secrete TSG-6 in vivo after intravenous administration and the efficacy of TSG-6 
declined with waiting time after injury occurred.54, 55. However, despite these 
efforts in improving the study design, we still weren’t able to find any 
improvement in limb necrosis subsequent to hASC treatment (Figure 20A), most 
likely due to the large variability within each group as we have seen before 
(Figure 20B). 
	   67 
 
Figure 20. Effects of human ASC on limb necrosis.  
(A) Progression of limb necrosis after surgery. Two hours after surgery, BALB/c 
mice were injected i.v. with 1 X 106 human ASC not transfected (ASCNT), 
transfected with TSG-6 siRNA (ASCTS), or with control scramble siRNA (ASCSC). 
(B) Large individual variability was observed in all treatment groups. No 
statistically significant difference was observed among groups. Mean ± SEM, 
n=7/group. 
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Involvement of TSG-6 in ASC-enhanced blood flow recovery 
Compared to necrosis score, laser Doppler imaging of blood flow is a 
more objective and commonly used method to evaluate the recovery from 
femoral artery obstruction. We have previously shown that human ASC i.v. 24 
hrs after femoral artery ligation improved blood flow recovery in NSG mice. In this 
study, we followed our routine injection protocol but knocked down TSG-6 in 
human ASC by siRNA before injection. As expected, regular ASC enhanced 
blood flow recovery compared to vehicle control and the difference reached 
statistical significance 2 weeks after surgery (Figure 21A). This therapeutic effect 
of ASC was lost when cells were transfected with siRNA, which seemed to have 
a nonspecific effect since TSG-6 siRNA and scramble RNA both weakened the 
potency of human ASC (Figure 21B).  
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Figure 21. Effects of human ASC on blood reperfusion of ischemic limb. 
(A) One day after surgery, NSG mice were injected i.v. with 1 X 106 human ASC 
not transfected (ASCNT), transfected with TSG-6 siRNA (ASCTS), or with control 
scramble siRNA (ASCSC). (B) Compared to the PBS control, the therapeutic 
effect of ASC became significant 2 weeks after surgery. No significant 
improvement was observed in ASCTS or ASCSC group. Mean ± SEM, n=6-7. 
*p<0.05.  
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3.4 Conclusion 
We successfully optimized human TSG-6 ELISA and established murine 
TSG-6 ELISA to quantify TSG-6 protein. Afterwards, we verified the effectiveness 
of knockdown of hTSG-6 in human ASC and reduced secretion of mTSG-6 from 
murine ASCko. Although femoral artery ligation did result in limb necrosis and 
gastrocnemius muscle atrophy in BALB/c mouse strain, the individual variability 
was too high to detect any difference between regular ASC and ASC with TSG-6 
knocked down. TSG-6 siRNA had no specific effect on blood flow recovery after 
femoral artery occlusion. 
 
3.5 Discussion 
The advantage of using murine ASC is that TSG-6 could be permanently 
knocked out (or down depending on ELISA protocols). The disadvantage, 
however, is that cell supplies may be limited because murine ASC are much 
more difficult to grow and senesce at early passages.  
Using same murine TSG-6 antibodies but different sources of standard 
recombinant murine TSG-6 protein, we saw a 10-fold difference in the dose of 
TSG-6 protein required to produce the same OD values (absorbance). This 
underlines the importance to factor in the source of standard proteins when 
comparing TSG-6 quantities among studies. From this perspective, an ELISA 
based on commercially available reagents enables easier sharing and 
comparisons of results from different studies. Similarly, the discrepancy between 
our hTSG-6 standard curve and the one from Prockop lab using the same 
protocol may result from different batches of standard TSG-6 proteins. 
Intriguingly, the response of limb muscles to femoral artery ligation varies 
dramatically among different mouse strains. Based on literature and our own 
experience, skin discoloration or limb necrosis seldom manifested in C57BL/6 
and NSG strain, whereas the severity of these symptoms varies among 
individuals in A/J, CSS, and nude mice.118 We chose BALB/c mice because they 
not only develop severe limb necrosis but also respond to local injections of 
BMSC.120 That said, their symptoms of limb necrosis also varied between grade 
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1 and 3 (on a scale of 0-4).118 To further reduce potential variability, we graded 
the severity of necrosis from 0 to 8 instead of commonly used grading of 0 to 4. 
Nevertheless, large variability of necrosis score persisted and no benefit from 
local injections of murine ASC or systemic injections of human ASC were 
recorded.  
The large individual variability of limb necrosis in BALB/c mice renders 
limb necrosis score a less sensitive endpoint to assess the efficacy of treatment. 
However, one might still be able to detect a potential therapeutic effect if 
optimizing conditions that would enhance the magnitude of the effect. Notably, in 
the previous BMSC study, the window of cell delivery was changed from 
immediately after femoral ligation to 24 hrs post-ligation because the former 
failed to improve flow recovery.120 This example underlined the importance of 
pharmacodynamic factors to the overall effect of injected cells. Therefore, to 
maximize any potential anti-inflammatory effect ASC may have, it is essential to 
optimize injection parameters such as cell passage, dosage, injection site, etc.  
In addition, another study pointed out that the stability of limb necrosis 
also depends on the anatomic location of ligations.122 Specifically, more 
variations were observed when the femoral artery was ligated proximal to the 
branch of popliteal artery (as was done in this study), possibly due to the 
variability in compensations from collateral circulation. The stability of limb 
necrosis can be largely improved by extending the resected segment to include 
popliteal artery branch, therefore blocking collateral blood flow compensations.  
Alternatively, other more sensitive inflammatory disease models may be 
employed to investigate the involvement of TSG-6 in the therapeutic effect of 
ASC. In the next chapter we used a murine model of cigarette smoking, which 
has been known to cause systemic inflammation. 
  
	   72 
Chapter 4. Rejuvenation of Smoking-induced Bone Marrow Progenitor 
Exhaustion: Moving from Adipose-Derived Stem Cells to Their Secretome 
4.1 Introduction 
Proinflammatory cytokines such as TNFα and IFNγ released in 
inflammation have been shown to potently suppress hematopoiesis.83, 123 The 
bone marrow (BM) has traditionally been viewed as a hematopoiesis organ to 
produce blood cells for daily physiological needs. In recent years, it has been 
increasingly recognized as a residence niche for stem and progenitor cells that 
can be mobilized to contribute to homeostasis and tissue repair of extra-
medullary organs.124-126 Depletion or even functional exhaustion of bone marrow 
reservoir of stem / progenitor cell has been correlated with worse prognosis and 
higher morbidity of numerous diseases including coronary heart disease, chronic 
obstructive pulmonary disease (COPD), diabetes, etc.127-132  
Cigarette smoking (CS) is a major risk factor for atherosclerotic vascular 
disease, COPD, and cancer.63, 133-135 In addition, it also has well-known adverse 
effects on other organ systems including kidney, liver, reproduction, and innate 
immunity.136-140 In contrast, the effect of CS on bone marrow stem/progenitor 
cells has been much less explored. Previous studies revealed a reduction of 
hematopoietic progenitors after mice were exposed to CS for 3 weeks.70, 72 This 
echoes with the clinical observations that exposure to CS or its active ingredient 
nicotine correlates with worse outcomes of patients receiving HSC 
transplantation and inferior colonization of fetal bone marrow by HSC.69, 141 The 
progression of and countermeasure for this CS-induced bone marrow 
dysfunction remain unknown. 
Adipose stem or stromal cells (ASC), which reside in the “non-adipocyte” 
fraction of the adipose tissue, represent a particularly feasible form of cell therapy 
for tissue repair and rescue from injury due to the easy access through 
liposuction. Several reports have described their capability to facilitate normal 
hematopoiesis, much resembling their counterpart marrow stromal cells.99, 142 
They have not been tested, however, as a countermeasure to correct bone 
marrow progenitor dysfunctions, including those caused by cigarette smoking. 
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Moreover, after intravenous administration, these cells usually home to the lung 
and release various paracrine factors contributing to the protection and recovery 
of injuries in distant organ systems.117, 143, 144 
In a previous chronic CS-induced murine emphysema model, we 
serendipitously observed a marked reduction of BM progenitors in addition to 
typical emphysematous abnormalities in the lung, both of which can be corrected 
by periodic injection (i.v.) of murine ASC.145 In this study, we shortened the 
exposure time to trace the beginning of CS-induced BM dysfunction. We used 
xenograft human ASC (hASC), which translate more easily into future clinical 
therapy, to counteract the effect of CS. We also, successfully identified specific 
cytokine TSG-6, previously not been recognized in the ASC secretome, to be the 
key factor responsible for the potent activity of hASC in this model.  
 
4.2 Materials and Methods 
Cell culture 
Human ASC were isolated and cultured as described in Chapter 2.  
 
Animals 
Animal studies were approved by the Animal Care and Use Committee of 
Indiana University. In vivo CS exposure was performed as previously 
described.146 Briefly, mice were exposed to 11% mainstream and 89% side-
stream smoke from reference cigarettes (3R4F; Tobacco Research Institute) 
using a Teague 10E whole body exposure apparatus (Teague Enterprise). The 
exposure chamber atmosphere was monitored for total suspended particulates 
(average, 90 mg/m3) and carbon monoxide (average, 350 ppm). For short-term 
exposure, C57BL/6 (female, age 6-8 wks, Jackson Laboratories) mice were 
exposed to CS for 1 day or 3 days (5 hrs/day). A bolus dose of 3 X 105 hASC 
was injected (tail vein, i.v.) before 1-day CS or after day 2 of 3-day CS. PBS was 
used as a control vehicle. For intermediate-term exposure, C57BL/6 were 
exposed to CS for 7 weeks (5 hrs/day, 5 days/week) and received weekly 
injection (i.v.) of 3 X 105 hASC. For long-term exposure, NSG mice were exposed 
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to CS for 6 months (5 hrs/day, 5 days/week) and received weekly injection (i.v.) 
of 2.5 X 105 hASC starting from 3rd month of CS (Figure 22). In all CS 
experiments, mice were euthanized and lungs were processed as previously 
described the day after the last day of CS exposure.147 
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Figure 22. Schedule of in vivo cigarette smoking (CS) exposure and hASC 
administrations.  
C57BL/6 mice were exposed to short or intermediate-term CS and received 
either bolus or weekly injections of 3 X 105 human ASC (hASC) or vehicle 
control. NSG mice were exposed to long-term CS and received weekly hASC 
(2.5 X 105 / mouse) after smoking for 2 months.  
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CS Extract Preparation 
An aqueous CS extract was prepared from filtered research-grade 
cigarettes (1R3F) from the Kentucky Tobacco Research and Development 
Center at the University of Kentucky. A stock (100%) CS extract was prepared by 
bubbling smoke from two cigarettes into 20 ml of basal culture medium (EBM2, 
Lonza) at a rate of one cigarette per minute to 0.5 cm above the filter, as 
previously described.146 The extract’s pH was adjusted to 7.4, followed by 
filtration (0.2 mm, 25 mm, Acrodisc) and used in cell culture experiments within 
20 min. A similar procedure was used to prepare the control extract, replacing 
the CS with ambient air. 
 
Clonogenic Progenitor Cell Assay 
Bone marrow from mice were assessed for granulocyte-macrophage 
colony-forming unit (CFU-GM), erythroid burst-forming unit (BFU-E), and 
multipotential granulocyte, erythroid, monocyte, megakaryocyte colony-forming 
units (CFU-GEMM) progenitor cells, as previously described.148, 149 In short, BM 
cells were flushed from both femurs, and plated at 5 X 104 cells/ml in 0.9% 
methylcellulose culture medium with 30% FBS (Hyclone), and 1 U/ml 
recombinant human erythropoietin (Epo, Amgen Corp), 50 ng/ml recombinant 
murine stem cell factor (rmuSCF, R&D Systems), 2 mM glutamine (Cambrex Bio 
Science), 10−4 M 2-mercaptoethanol (Fisher Scientific), 0.1 mM hemin (Sigma-
Aldrich) and 5% vol./vol. pokeweed mitogen mouse spleen cell conditional 
medium. For in vitro CSE toxicity assay assessing CFU-GM only, 5 X 104 cells 
were plated and cultured in 0.3% methylcellulose culture medium in the presence 
of 50 ng/mL rmuSCF and 10 ng/mL recombinant murine GM-CSF (rmuGM-CSF, 
R&D Systems). Absolute numbers of progenitors were calculated from the 
nucleated cellularity per femur and the number of colonies formed per number of 
cells plated. The percentage of progenitors in the S phase of the cell cycle was 
estimated by use of the tritiated thymidine kill technique, as described 
previously.149 Colonies were scored by two blinded readers (Figure 23) after 7 
days of incubation at 37°C, in lowered (5%) O2 and 5% CO2. The high specific 
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activity tritiated thymidine kill assay allows an estimate of the cell cycling status of 
progenitors by analysis of the percent progenitors in S-phase at time cells were 
removed from mice and plated.  
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Figure 23. Correlation between 2 blinded readers for the CFU assays. 
CFU-GM colonies in plates from different experiments were scored by two 
blinded readers for colony numbers. 
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Phenotypic Analysis of Bone Marrow Stem and Progenitor Cells 
The following phenotypically identified stem and progenitor cell 
populations were assessed in the bone marrow (BM): lineage−Sca1+c-Kit+ cells 
(LSK, enriched for hematopoietic stem cells), multi-potent progenitors 
(CD34+CD135+ LSK), common lymphoid progenitor (CLP; Lin−Sca1+c-Kit+IL-
7Rα+), common myeloid progenitor (CMP; Lin−Sca1−c-Kit+CD34+FcγR−/low), and 
granulocyte/macrophage progenitor (GMP; Lin−Sca1−c-Kit+CD34+FcγR+/high). BM 
was collected and stained with antibodies to surface markers previously 
described.150 Anti-mouse antibodies c-Kit, Sca1, FcγR, IL7Rα, Lineage Cocktail, 
and isotype controls were purchased from BD Biosciences. Anti-mouse CD34 
antibody was purchased from eBioscience and Sca1 was also purchased from 
BioLegend. Data was collected from the samples using a LSR II (BD 
Biosciences) instrument and BD FACSDiva software (BD Biosciences), and was 
analyzed using Flowjo software (Tree Star). 
 
Cell Cycle Analysis of Bone Marrow Sca1+ Progenitor Cells 
Total mouse bone marrow cells were stained with FITC-Sca1 antibody 
(BD Biosciences) and sorted for Sca1+ cells on Reflection II (BD Biosciences). 
Cell cycling staining was performed as previously described.151 Briefly, cells (5 X 
103) were washed with PBS containing 0.1% BSA and incubated with 5 mg/ml of 
RNase A (DNase free) and 50 mg/ml propidium iodide (PI) for 15 min at room 
temperature. The percentages of cells in various phases of the cell cycle were 
measured with a FACSCalibur flow cytometer (BD Biosciences). 
 
Histology of Bone Marrow Cellularity in Femur 
The right femur of each mouse was harvested and fixed in 4% phosphate 
buffered formalin (PBF) for 48 hrs, after which it was demineralized in a solution 
of 10% EDTA and 4% PBF (7:3 ratio) at 4°C with agitation for a week. Femurs 
were then embedded in paraffin and longitudinally sectioned at 4 µm. Two slides 
from each femur were stained with hematoxylin and eosin (H&E) for microscopic 
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examination. To stain proliferative cells, one slide from each femur was stained 
with rabbit anti-mouse Ki-67 antibody (Abcam). 
 
RNA Extraction and Quantitative Real-Time PCR 
Whole lungs were perfused free of blood via right ventricular perfusion 
with 10 ml warmed saline, rapidly excised en bloc, blotted, and snap-frozen in 
liquid nitrogen. Total RNA was extracted from lung homogenates using the 
RNeasy mini kit (Qiagen) following manufacturer’s instructions. Reverse 
transcription with High-Capacity cDNA Archive Kit (Applied Biosystems) and 
triplicate real-time PCR with SYBR Green Master Mix (Applied Biosystems) and 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) internal control were 
carried out as previously described.152  
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Table 1. The sequences of the polymerase chain reaction (PCR) 
amplification primers 
Gene Primers (5' -> 3') Product size (bp) 
murine TNFα 5'-CTGAACTTCGGGGTGATCGG-3' 121 
 
5'-GGCTTGTCACTCGAATTTTGAGA-3'   
murine IL1β 5'-GCAACTGTTCCTGAACTCAACT-3' 88 
 
5'-ATCTTTTGGGGTCCGTCAACT-3' 
 murine GAPDH 5'-AGGTCGGTGTGAACGGATTTG-3' 122 
 
5'-TGTAGACCATGTAGTTGAGGTCA-3' 
 human TSG-6 5'-ACCACAGAGAAGCACGGTCT-3' 159 
  5'-CTGCCCTTAGCCATCCATCC-3'   
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Transfection of hASC with TSG-6 siRNA 
Knockdown of TSG-6 by siRNA and verification of TSG-6 levels by ELISA 
were described in Chapter 2.  
 
Statistical Analyses 
Data are shown as mean ± SEM. Comparisons between two groups were 
made with the use of ANOVA and Newman-Keuls post-hoc analysis. A p value of 
< 0.05 was considered significant. 
 
4.3 Results 
Acute reduction and slow recovery of clonogenic BM progenitor cells after CS 
and effect of hASC 
Khaldoyanidi first noticed the decline of bone marrow myeloid 
progenitors when they exposed BALB/c mice to CS for 3 weeks.70 In our study 
using C57BL/6 mice, we surprisingly found this adverse effect of CS occurred 
much more acutely – CFU-GM started declining up to 35% after only 1 day of CS 
exposure, which can be prevented by a bolus injection (i.v.) of 3 X 105 human 
ASC before smoking (Figure 24A). This acute effect was less prominent on BFU-
E and CFU-GEMM (Figure 24B and C).  
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Figure 24. ASC prevent CFU-GM from acute suppression caused by one 
day of cigarette smoke exposure.  
C57BL/6 mice were injected with 3 X 105 human ASC i.v. before exposure to air 
or smoke for 1 day. CFU-GM: colony forming unit– granulocyte, monocyte; BFU-
E: burst forming unit–erythroid; CFU-GEMM: colony forming unit–granulocyte, 
erythrocyte, monocyte, and megakaryocyte. Mean ± SEM, n=3 mice/group. 
*p<0.05, **p<0.01. 
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After extended exposure (3 days), CFU-GM counts continued to decline 
– by approximately 40%; and the toxicity of CS extended to other CFUs such as 
BFU-E and CFU-GEMM, which decreased by approximately 55% and 50%, 
respectively (Figure 25). These different types of progenitors not only differ in 
their sensitivity to CS but also in their rate of post-CS recovery. For instance, 
CFU-GM and CFU-GEMM were not fully recovered after cessation of CS for 
twice as long as exposure time. Given the hematopoiesis-supporting nature of 
adipose stem cells and our previous success using them to reverse systemic CS 
toxicity in chronic smoking mice, we tested bolus injection (i.v.) of xenograft 
human ASC as a countermeasure in this acute smoking model. To mimic 
treatment window for patients with smoking history, cells were administered in 
the middle of the entire CS period (after day 2 of 3-day CS exposure). 
Remarkably, ASC restored all 3 lineages of progenitors to levels even higher 
than those after 7 days of recovery, much close to the nonsmoker level (Figure 
25).  
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Figure 25. Self-recovery of mouse bone marrow hematopoietic progenitor 
cells after 3-day CS and effect of ASC.  
C57BL/6 mice were exposed to air or cigarette smoke (CS) for 3 days then 
rested for 1-7 days (D1-D7) for recovery. One additional group received a bolus 3 
X 105 human ASC i.v. after day 2 and bone marrow were harvested one day after 
last CS exposure. CFU-GM: colony forming unit– granulocyte, monocyte; BFU-E: 
burst forming unit–erythroid; CFU-GEMM: colony forming unit–granulocyte, 
erythrocyte, monocyte, and megakaryocyte. Mean ± SEM, n=3-6 mice/group. 
ap<0.05 (vs. air), bp<0.05 (vs. day 1). 
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Exhaustion of phenotypic stem and progenitor cells with prolonged exposure and 
effect of hASC 
Notably, the rapid loss of functionally defined (based on clonogenic 
capacity) progenitors occurred latently without changes of total cellularity in the 
bone marrow cavity (Figure 26 and 27A) and couldn’t be detected in early phase 
(3 days) by flow cytometry based on commonly used phenotype markers (Figure 
27). The distinct contrast between dramatic change in clonogenic capacity and 
lack of change in phenotype identity indicate that while phenotypic markers may 
help distinguish progenitor cells from mature cells, they offer no information on 
the functionality and physiological status of BM stem and progenitor cells. This 
speculation directed our later efforts to studying functionality of progenitor cells 
using colony-forming-unit assays. In addition, it also supports the notion that 
changes in functionality of BM progenitors precede changes in their phenotype. 
To prove this hypothesis, we extended the exposure time to 7 weeks. As 
expected, we observed a significant reduction (by early 60%) of Lineage- Sca1+ 
c-Kit+ bone marrow cells, which are enriched with stem and progenitor cells. 
Consistent with findings in the acute model, weekly injection of human ASC was 
able to fully reverse the damage to the level of nonsmoking mice (Figure 28B). 
These data demonstrate that ASC were able to protect BM stem and progenitors 
from CS-induced depletion, possibly by reversing the exhausted clonogenic 
capacity caused by CS at early stage.  
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Figure 26. H&E staining of distal femur showing lack of change in bone 
marrow cavity structure and cell distribution after treatment.  
Right femurs were harvested from C57BL/6 mice exposed to 3-day smoking, 
demineralized, paraffin-embedded, longitudinally sectioned, and stained with 
hematoxylin and eosin (H&E). Images showed the distal end of each femur.  
Air control
Smoke + PBS
Smoke + ASC
Smoke + TSG6
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Figure 27. Phenotypic progenitors remain unchanged after 3-day CS.  
(A) Settings for multi-color flow analysis of phenotypic hematopoietic stem and 
progenitor cells. MPP: Multi-Potent Progenitors; GMP: Granulocyte-Macrophage 
Progenitors; CMP: Common Myeloid Progenitors; CLP: Common Lymphoid 
Progenitors. (B) C57BL/6 mice were exposed to 3-day ambient air (AC) or 
cigarette smoke (CS). No difference was observed for various phenotypic 
progenitors (n=6/group).  
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Figure 28. Prolonged CS-induced depletion of phenotypic hematopoietic 
stem / progenitor cells and effects of human ASC.  
After extended exposure to CS (from 3 days to 7 weeks, 5 hrs/day), although 
total bone marrow cellularity remains unchanged (A), Lin-Sca1+c-Kit+ cells 
(enriched for hematopoietic stem and progenitor cells) significantly reduced (B). 
For 3d-smoking mice, 3 X 105 hASC were injected i.v. after day 2. For 7wk-
smoking mice, 3 X 105 hASC was injected i.v. weekly. Total bone marrow cells 
were flushed from both femurs and counted using a Hemavet (Drew Scientific) 
instrument (n=11/group for 3d-smoking, 3/group for 7wk-smoking). LSK were 
quantified by flow cytometry (n=3/group). Mean ± SEM. *p<0.05. 
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Absence of Injected hASC in Mouse Bone Marrow  
In search for mechanisms underlying therapeutic effects of ASC 
observed above, our first theory was that the effect came from locally engrafted 
ASC. After all, in certain disease models, systemically delivered hASC were able 
to home to the site of injury and contribute to tissue regeneration. If this indeed 
occurred also in smoking mice, the best chance to capture engrafted hASC in 
mouse bone marrow is to collect total mouse bone marrow and stain for human-
specific antigens. Therefore, we isolated total bone marrow cells from 
immunotolerant NSG mice (to exclude the possibility of immune rejection to 
xeno-transplanted cells) receiving weekly hASC for 4 months (to accumulate 
more engrafted hASC) and plated them on plastic surface. After 7 days, medium 
was replaced to remove unattached hematopoietic cells and the attached cells 
(hASC adhere to plastic surface) were stained with anti-human nuclei Ab. 
Surprisingly, we were not able to find any human cells (Figure 29), which 
suggests hASC were more likely to function remotely through paracrine factors. 
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Figure 29. Absence of human cell engraftment in NSG mice receiving 
intravenous hASC.  
NSG mice were exposed to 6 months of cigarette smoking and administered i.v. 
with human ASC weekly since the 3rd month. Total bone marrow cells were 
harvested from 2 femurs and plated on plastic in DMEM/10%FBS. Cells were 
stained with mouse anti-human nuclei Ab. Human ASC were used as positive 
control. Murine endothelial cells were used as negative control. 
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ASC respond to CS-induced host inflammatory cytokines by secretion of TSG-6 
We have previously shown that intravenously injected ASC were 
transiently trapped in the lung,146 where they may be exposed to inflammatory 
mediators produced in lungs exposed to CS153. Given that our data described in 
chapter 2 showed secretion of TSG-6 from ASC was triggered by environmental 
inflammatory signals, we measured the inflammatory cytokine secretion in the 
lung and the TSG-6 expression in the lungs exposed to CS at a time when ASC 
were found in the lung. Increased release of proinflammatory cytokines is a 
hallmark of CS-related pathophysiology.153 As expected, we observed a marked 
increase of TNFα (by 4.1 fold) and IL1β (by 3.9 fold) transcripts in the lungs 
exposed to CS (Figure 30A). In this context, a recent study also demonstrated 
that stromal cells from bone marrow trapped in the lung after i.v. delivery were 
activated by TNFα to secrete anti-inflammatory cytokine TSG-6.54 Indeed, using 
human-specific primers for TSG-6 gene, we detected high levels of human TSG-
6 transcripts in lung from mice receiving hASC (Figure 30B). To further elucidate 
this feedback mechanism of hASC responding to host pro-inflammatory signals, 
we measured secretion of TSG-6 from ASC in vitro cells were treated with TNFα 
or IL1β. After incubation with 20 ng/ml human TNFα or IL1β for 24 hours, TSG-6 
secretion increased from undetectable levels to over 5.0-8.7 ng/103 cells in 24 
hrs (Figure 31A). Moreover, in parallel experiments, mouse TNFα or IL1β 
demonstrated equivalent stimulatory effects on human ASC (Figure 31B), 
suggesting a dynamic cross-species interaction between the host environment 
and injected xenograft human cells. This activated TSG-6 secretion from ASC in 
the context of smoking-induced lung inflammation highly warrants further 
investigation into potential role of this protein in mitigating CS toxicity. 
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Figure 30. Increased murine inflammatory cytokines and human TSG-6 
transcripts in lungs of smoking mice.  
(A) Expression of both murine TNFα and IL1β were up-regulated in the lung after 
mice were exposed to 3-day cigarette smoking (CS) compared to air control 
(AC); (B) minimum human-specific TSG-6 mRNAs were detected in untreated 
mouse lungs, which markedly increased 40 hrs after intravenous injection of 
human ASC. Mean ± SEM, n=3. *p<0.05; **p<0.01. 
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Figure 31. Both human and murine TNFα and IL1β activate human ASC to 
secrete TSG-6. 
(A) In vitro, secretion of TSG-6 protein from human ASC is low at baseline but 
strongly increased after stimulation of human pro-inflammatory cytokines (TNFα 
and IL1β, but not IFNγ); (B) secretion of TSG-6 from hASC can be activated 
similarly with cross-species mouse pro-inflammatory cytokines. Mean ± SEM, 
n=3. **p<0.01.  
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TSG-6 directly antagonizes myelotoxicity of smoking 
TSG-6 may attenuate the myelotoxicity of smoking through two 
mechanisms: one is to directly block effects of toxins (including pro-inflammatory 
cytokines such as TNFα) on bone marrow progenitors, the other is to reduce the 
amount of toxins resulted from smoking. To test the first possibility, we 
established an in vitro model using cigarette smoke extract as a substitute for the 
mixture of dissolved circulatory compounds derived from smoke. We only looked 
at CFU-GM colonies because they consist of 90% of all colonies and is a more 
accurate indicator. In accordance with in vivo observations, CFU-GM decreased 
by 75.1% after treatment of 1.5% CSE for 7 days. This direct toxicity of smoke-
derived compounds can be fully antagonized by co-cultured hASC or 
supplemented ASC-conditioned media, and partially attenuated by recombinant 
TSG-6 protein (0.5 µg/ml), but not by conditioned media from ASC in which TSG-
6 secretion was silenced (Figure 32). These data support the novel application of 
TSG-6, in addition to its anti-inflammatory functions, as an antagonist against 
myelotoxins such as those derived from smoke. They also highlighted the critical 
role TSG-6 played in mediating antagonistic effects of ASC secretome against 
toxicity of CSE in vitro.  
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Figure 32. Protection of GM-CFU by ASC, ASC conditioned media, and 
TSG-6 from toxicity of cigarette smoke extract (CSE) in vitro.  
Mouse bone marrow cells were treated in vitro with 1.5% CSE with or without 
ASC / ASC-CM / TSG-6 in methylcellulose medium supplemented with FBS, 
mGM-CSF (10 ng/ml) & mSCF (50 ng/ml) for 7 days. Mean ± SEM, n=3/group. 
ap<0.05, (vs. non-treated control); bp<0.05, vs. (CSE + vehicle). ASCNT=Non-
transfected ASC; ASCTS=TSG-6 siRNA-transfected; ASCSC=scramble RNA-
transfected. 
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TSG-6 is a key mediator for myeloprotective effects of hASC 
To determine the role of TSG-6 in the myeloprotective effect of hASC in 
vivo, equal amounts (3 X 105) of hASC either not transfected, or transfected with 
TSG-6 siRNA or scramble siRNA were administered after day 2 of 3-day CS 
exposure. Analysis of bone marrow revealed that non-transfected or scramble 
siRNA-transfected hASC were still capable of reversing the significant decrease 
of CFU-GM and BFU-E subsequent to smoking, while hASC transfected with 
TSG-6 siRNA almost completely lost their therapeutic effect (Figure 33A and B). 
Changes of CFU-GEMM were not statistically significant due to high variability 
but had the same trend as CFU-GM and BFU-E (Figure 33C). These results 
suggest that TSG-6 is a key mediator of myeloprotective functions of hASC in 
vivo. 
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Figure 33. Myeloprotective effects of hASC were lost after TSG-6 
knockdown.  
C57BL/6 mice were exposed to 3-day CS and injected i.v. with 3 X 105 hASC 
either not transfected (ASCNT), or transfected with TSG-6 siRNA (ASCTS) or with 
control scramble siRNA (ASCSC) after day 2. Mean ± SEM, n=6/group. ap<0.05 
(vs. AC); bp<0.05, (vs. vehicle). 
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Effects of hASC can be reproduced by hASC-conditioned medium and TSG-6  
Conditioned media with active ingredients have numerous advantages 
over producer cells per se from application perspectives. Cell-free conditioned 
media also help avoid potential side effects from rejections to allogeneic or 
xenograft cell transplantation by the host environment. Given the importance of 
trophic factors, including TSG-6 to the effect of hASC, we next attempted to 
replace cells with their conditioned media. As expected, conditioned media from 
TNFα-activated regular hASC fully recapitulated the therapeutic effect of 
producer cells. In contrast when TSG-6 was knocked down in hASC, the efficacy 
of the derived conditioned media was also reduced, which could be compensated 
by supplementing additional exogenous recombinant TSG-6 protein. These data 
highlighted TSG-6 as a critical ingredient in ASC-conditioned media and 
therefore its potential usefulness as an indicator for the quality control of ASC 
conditioned media. Notably, the concentration of recombinant TSG-6 protein 
alone necessary to achieve the same effect as conditioned media was at least 10 
fold higher than the concentration of endogenous TSG-6 present in conditioned 
media (as measured by ELISA) (Figure 34A). This indicated that either the 
recombinant TSG-6 protein, produced in a mouse myeloma cell line, was of 
weaker potency than that naturally secreted by human ASC due to different 
folding, for example, or that there are other yet unknown in the conditioned media 
that synergize with TSG-6 to enhance its efficacy (Figure 34A).  
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Figure 34. Effects of ASC against myelotoxicity of cigarette smoke can be 
reproduced by ASC conditioned medium and higher dose of TSG-6.  
C57BL/6 mice were exposed to sham air or 3-day CS and injected i.v. with 
following treatment groups: 1) vehicle; 2) 3 X 105 hASC; 3) conditioned media 
from non-transfected hASC(ASCNT), 4) & 5) from hASC transfected with TSG-6 
siRNA (ASCTS) with or without supplement of 0.2 µg recombinant human TSG-6 
(rhTSG-6), or 6) from hASC transfected with control scramble siRNA (ASCSC); 7) 
0.2 µg rhTSG-6; 8) 2 µg rhTSG-6. Conditioned medium from ASC demonstrated 
equivalent effects as producer cells, which was compromised by loss of the key 
component TSG-6. Supplementing the lost amount of TSG-6 in conditioned 
medium with recombinant TSG-6 protein restored the efficacy of conditioned 
medium. The therapeutic effect of TSG-6 protein can be significantly enhanced 
(by ~10 fold) when synergized with other components in conditioned medium. 
Cell cycling (right) has a more sensitive response to treatment than absolute 
number of progenitors (left). Mean ± SEM, n=3/group. ap<0.05 (vs. AC); bp<0.05, 
(vs. vehicle). 
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ASC restored CS-induced cycling arrest of bone marrow progenitors 
Slow or non-cycling state could be a key contributor to decreased 
clonogenic capacity of bone marrow progenitors observed above. To test this 
hypothesis, we assessed the cycling status of bone marrow progenitors from 
above treatment groups. Indeed, the percentage of immature progenitor cells in 
the S phase of the cell cycle (killed by tritiated thymidine in the assay) 
significantly decreased (CFU-GM by 75.8%, BFU-E by 90.5%, and CFU-GEMM 
by 93.2%) after 3-day CS but could be fully rescued by hASC, ASC-conditioned 
media, or excessive TSG-6 (Figure 34B). These results were consistent with 
previously observed trend of changes in progenitor numbers but with greater 
degree of difference among groups, suggesting cell cycling as a more sensitive 
indicator for outcomes of smoking and hASC treatment. In addition to clonogenic 
progenitors, ASC also enhanced cycling of primitive hematopoietic progenitors 
(Sca1+) by almost 3-fold (Figure 35). 
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Figure 35. Increased cycling of Sca1+ BM cells after hASC treatment.  
Sca1+ bone marrow (BM) cells were sorted from mice exposed to air (AC) or 3-
day cigarette smoking (CS) with or without injection of human ASC after Day 2. 
Cell cycling was evaluated by staining nuclei with propidium iodide and analyzing 
on flow cytometer.  
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4.4 Conclusion 
Our results in Chapter 4 showed that cigarette smoke-derived toxic 
compounds caused acute cycling arrest and deficient clonogenicity of bone 
marrow hematopoietic progenitor cells (HPC), which progressed to depletion of 
phenotypic HPC after extended exposure. A single dose of 3 X 105 human ASC 
(i.v.) in midst of short-term exposure (3 days) and weekly repeated doses during 
chronic exposure (7 weeks) were both sufficient to reverse bone marrow 
progenitor deficiency caused by smoking. Notably the acute toxicity of smoke on 
bone marrow is also accompanied by upregulation of inflammatory cytokines 
such as TNFα and IL1β in the lung, which triggered secretion of TSG-6, likely 
from ASC infused i.v. and trapped in the lung. Conditioned media from ASC as 
well as TSG-6 (though less effectively) antagonized myelosuppressive effects of 
chemical compounds in cigarette smoke extract in the in vitro colony-forming-unit 
assay, suggesting potent antagonistic effects from trophic factors secreted by 
ASC, especially TSG-6. Our further knockdown experiments in vivo showed that 
knockdown of TSG-6 in ASC or absence of TSG-6 in the ASC conditioned media 
results in almost complete loss of the therapeutic effect previously observed with 
regular ASC or conditioned media. Moreover, this lack of effect from ASC 
conditioned media can be compensated by supplementing the missing amount of 
TSG-6 protein, which by itself at much higher dose was sufficient to reverse the 
myelotoxicity of smoke in vivo.  
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4.5 Discussion 
The widely distributed detrimental effects of cigarette smoking have 
previously been attributed to systemic inflammation, oxidative stress, endothelial 
injury, and hemodynamic dysfunctions.60, 62, 154-156 Little attention has been paid 
to the involvement of bone morrow progenitor cells in the pathogenesis of 
smoking-related diseases. Our results showed that the CS-induced damage in 
the bone marrow occurred rather acutely (1-3 days), well preceding the 
development of emphysema in the lung (typically 6 months), and certain types of 
progenitors (BFU-E and CFU-GEMM) recovered extremely slowly long after 
cessation of smoking. Given the importance of BM progenitor cells to peripheral 
tissue regeneration, it is highly likely that this early deficiency of maintenance 
cells subsequent to smoking contribute critically to the pathogenesis of numerous 
diseases related to cigarette smoking. To substantiate this hypothesis, it would 
be interesting to generate chimeric mice with bone marrow from smoking-
resistant strain and evaluate their susceptibility to CS-induced emphysema. 
Notably, this early pathological changes were limited to the functionality of 
hematopoietic progenitors and could be easily overlooked if only phenotypes 
were examined. This discrepancy between functionality and phenotype was also 
noted in other occasions, supporting functional assays as a more sensitive 
method to detect BM abnormality.157 
For most experiments reported here, we used immune-competent mice 
treated with human ASC despite the concern of xenograft rejections, for the 
following considerations. 1) Cigarette smoking has a major impact on the 
immune system, which may affect other organ systems secondarily,158, 159 which 
may increase its immunotolerance towards xenogeneic cell transplants; 2) 
mesenchymal stem cells lack HLA antigen and are immune-privileged;160 3) more 
than 99% of xenograft MSC are rapidly removed by host environment within 
48hrs after systemic administration;54 4) human ASC have exhibited potent 
cross-species paracrine activities in other disease models;161 5) findings from 
human ASC can be more easily translated into future clinical applications.  
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It has been increasingly recognized that the main therapeutic effect of 
intravenously delivered ASC originates from potent trophic factors released by 
the majority of cells trapped in the lung. That said, it is difficult to substitute hASC 
with their in vitro culture supernatant because secretome of hASC often adapt 
according to the interaction between hASC and their surrounding environment.162 
A recent study has demonstrated that another type of mesenchymal stem cells, 
BMSC, were able to secrete anti-inflammatory cytokine TSG-6 when trapped in 
the lung and stimulated with TNFα.54 This in combination with our observation of 
an acute increase of inflammatory cytokine expressions in the lung after mice 
started smoking has prompted our interest in investigation of whether TSG-6 also 
plays a role in the ASC effect on CS-induced injury. Indeed, our data clearly 
showed that hASC not only respond to hTNFα but also to other inflammatory 
stimuli such as IL1β. Moreover this feedback mechanism extends to cross-
species signals. Remarkably, we successfully substituted hASC with conditioned 
media generated based on this mechanism and established, for the first time, the 
importance of TSG-6 to the paracrine effect of hASC in the CS-induced BM 
hypoplasia model. These data laid a firm ground to the possibility of 
manufacturing more convenient off-the-shelf medical products to replace hASC 
at least for this indication so that the invasive liposuction procedure could be 
avoided.  
TSG-6 belongs to the hyaluronan-binding protein family. Its potent anti-
inflammatory effects have been demonstrated in multiple disease model and 
proposed mechanisms include binding to CD44 and interfering with NF-κb 
signaling pathway in macrophages to suppress TNFα secretion.47 Although pro-
inflammatory cytokine such as TNFα could inhibit hematopoiesis,83 in our in vitro 
model of CS extract-induced progenitor suppression, the adverse effect came 
more likely from the direct toxicity of compounds in the cigarette smoke. And 
hASC, ASC-conditioned medium, and TSG-6 were all capable of antagonizing 
the toxicity, in accordance with they efficacy in vivo. This discovery of anti-
myelosuppressive function of TSG-6 is unprecedented and may extend to other 
indications such as irradiation or chemotherapy-induced myelosuppression. That 
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said, the contribution of anti-inflammatory effect of TSG-6 to its overall benefit in 
the smoking model cannot be excluded, after all, we did observe a decline of 
TNFα transcripts in the lungs of mice treated with hASC. We also demonstrated, 
for the first time, that conditioned media from hASC if generated incorrectly (i.e. 
from hASC incapable of TSG-6 secretion) lack their expected efficacy. This may 
shed some light to previously failed attempts in other models to replace hASC 
with conditioned media. Remarkably, we were able to correct this flawed regime 
by supplementing the single missing component of TSG-6. It is worth pointing out 
though, despite the importance of TSG-6 to the effect of hASC, the efficacy of the 
cytokine alone is much lower than ASC-conditioned medium containing 
equivalent concentration of TSG-6. This indicates that there are other synergistic 
factors in the ASC-conditioned medium critical to the overall benefit but yet to be 
discovered. 
Our observation of smoking-induced exhaustion of hematopoietic 
progenitor cells seemed paradoxical to previously observed smoking-associated 
leukocytosis in peripheral blood.163 On a closer look, they are not mutually 
exclusive since we did find an increased proliferation of hematopoietic cells in the 
bone marrow (Figure 36), which is not resolved by hASC or TSG-6. Although the 
number of LSK cells (Figure 28) and the cycling of Sca1+ cells (Figure 35) were 
not affected by short-term (3 days) smoking, the high demand of hematopoiesis 
(Figure 36) and arrested cycling of clononenic progenitors (Figure 34B) could 
lead to exhaustion of HSC (LSK) and primitive progenitor cell (Sca1+ cells) 
repository in the long run (Figure 28). In contrast, although ASC and TSG-6 did 
not suppress downstream hematopoiesis demand, they reactivated cycling of 
upstream clonogenic (CFU-GM, BFU-E, and CFU-GEMM) and primitive 
progenitors (Sca1+ cells), therefore avoided depletion of HSC (LSK cells). 
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Figure 36. Ki-67 staining of total BM cells. 
Section slides of femurs from 3-day smoking mice were stained with rabbit anti-
mouse Ki-67. Cells in brown color were Ki-67+ proliferating cells. Images showed 
distal end of the femur. 
 
 
	   110 
Chapter 5. Future Directions 
5.1 Anti-inflammatory Aspect of ASC & TSG-6  
Molecular Mechanisms 
From a mechanistic standpoint of view, it would be of interest to further 
investigate target molecules in endothelial cells that are positioned downstream 
of TSG-6-mediated protection. Since CD44 is expressed abundantly on 
endothelial cells and has been confirmed to be a receptor for TSG-6 on 
macrophages, we plan to determine the expression and distribution of CD44 in 
endothelial cells before and after thrombin / TNFα / TSG-6 treatment. One 
previous study observed increased neutrophil transmigration subsequent to 
TNFα treatment and an inhibitory effect of TSG-6 link module. They excluded 
possible involvement of adhesion molecules in endothelial cells in this 
phenomenon by showing that TSG-6 link module did not change protein levels of 
the three key adhesion molecules ICAM-1, PECAM-1, and P-selectin in human 
bone marrow-derived endothelial cells. While this finding will have to be validated 
in our model, which uses TSG-6 whole protein and human umbilical vascular 
endothelial cells (HUVEC), we plan to also investigate potential changes in 
junction proteins (such as VE-cadherin) and the cell skeleton (such as F-actin), 
since they are more directly related to the regulation of inter-cellular gap 
formation and extravasation of neutrophils. If VE-cadherin is indeed affected, it 
would be interesting to further look into the VE-cadherin / β catenin signaling 
pathway, which has also been known to regulate permeability of HUVEC.  
 
Applications in Disease Models 
The protective effect on vascular barrier and inhibitory effect on 
lymphocyte proliferation we observed in vitro highly warrant further studies to test 
the efficacy of ASC and TSG-6 protein in relevant animal disease models. One 
example could be the abdominal aortic aneurysm (AAA). AAA is a highly 
insidious but fatal disease and comprises the 10th leading cause of death in men 
in the U.S. The only option for treatment is surgical repair, which is associated 
with significant morbidity, mortality, and expense. Vascular wall destruction 
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caused by MMP2 and MMP9 activation and excessive lymphocyte proliferation is 
the predominant event in the pathogenesis of AAA and the progression of the 
disease is directly related to inflammatory cytokine TNFα.164, 165 Our data showed 
that TSG-6 protected vascular barrier and inhibited lymphocyte proliferation. In 
combination with previous evidence that TSG-6 inhibits MMP2 and MMP9 
activation as well as TNFα release from macrophage, they strongly imply ASC 
and TSG-6 as novel promising therapies for AAA.  
 
5.2 Myeloprotective Aspect of ASC & TSG-6  
Effects of Smoking on HSC 
Our data from colony-forming-unit assays demonstrated an acute toxicity 
of CS on all 3 lineages of HPC, namely CFU-GM, BFU-E, and CFU-GEMM. 
Furthermore, the numeric change of Lin-Sca1+c-Kit+ cells (enriched for HSPC) 
suggested a possibility that with sufficient exposure, the toxicity of CS may also 
extend to HSC. To pursue this hypothesis, it is helpful to differentiate effects of 
CS on long-term HSC (CD34-CD135- LSK), short-term HSC (CD34+CD135- 
LSK), and MPP (CD34+CD135+ LSK) within the LSK cell population. If 
phenotypic short or long-term HSC were indeed reduced by CS, competitive 
repopulation assays could be used to further verify potential damages on 
functional HSC. Specifically, BM HSC from C57BL/6 mice (CD45.2+) treated with 
air, CS, or CS + ASC will be co-transplanted with BM HSC from BoyJ (CD45.1+) 
mice into recipient B6/BJ-F1 mice (CD45.1+ CD45.2+). Influence of CS and ASC 
on HSC will be determined by comparing engraftment of CD45.2+ cells in 
recipient mice 1, 2, 4, and 6 months after transplantation.  
 
Molecular Mechanisms 
To further dissect the molecular effectors for smoke / TSG-6, we plan to 
compare gene signatures of HPC among three treatment groups: air control, 
cigarette smoke, and cigarette smoke + ASC/TSG-6 and look for genes changed 
after smoke and reversed by ASC/TSG-6 treatment. The quantitative changes in 
LSK cells (enriched for hematopoietic stem and progenitor cells) from mice 
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exposed to 7-week CS suggest that phenotypic changes may become evident 
with long-term CS exposure, which allows for targeted analysis of different HPC 
populations, such as CMP, CLP, GMP, MPP, etc. Therefore, after changes in 
these phenotypic progenitors were confirmed, they could then be selected by 
flow cytometry and analyzed for regulatory genes by PCR arrays. High 
throughput PCR array will be necessary given the scarcity of LSK cells in the 
bone marrow. Information from high throughput arrays can then be verified by 
qPCR and Western blot to further narrow down the targets. We will then be able 
to design gain / loss-of-function experiments to modulate these factors and 
evaluate their impact at the cellular level.  
 
Effects of Smoking on Bone Marrow Niche Environment 
The toxicity of cigarette smoking may not only be restricted to bone 
marrow hematopoietic progenitor cells per se, but also extends to the entire 
niche environment of bone marrow. After all, studies have shown that smoking 
history is related to worse prognosis after bone marrow transplantation, which 
supports the notion that chronic smoke exposure may result in a harsh receptive 
bone marrow environment.69 If the bone marrow environment did suffer from 
smoking-induced malfunction, then in addition to cycling and clonogenicity, 
engraftment and mobilization of hematopoietic stem and progenitor cells (HSPC) 
may also be affected. The engraftment abnormality could be studied by 
transplantation of HSC from regular mice to recipient mice with or without 
previous exposure to smoking. And the mobilization dysfunction could be verified 
by comparing mobilized HSC in peripheral blood in mice exposed to smoking or 
ambient air. Deficient HSC mobilization, if verified, would shed some light into the 
rationale behind the correlation between smoking history and slower wound 
healing and worse prognosis of cardiovascular diseases.  
 
Hematological Applications of ASC and TSG-6 
Attempts to enhance engraftment of HSC with ASC have been made only 
in recent two years whereas TSG-6 has never been applied to hematological 
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indications. The remarkable protective effects of both in our model of smoking-
induced myelosuppression highly warrant further efforts to study them in the 
context of myelosuppression from other causes, such as irradiation and 
chemotherapy. After all, many etiological factors responsible for 
myelosuppression such as oxidative stress and inflammation are shared by 
smoking and irradiation / chemotherapy. Besides, the quick recovery of cell 
cycling as a result of ASC / TSG-6 treatment could contribute to the recovery of 
diminished viable stem / progenitor cell repository from harsh myelotoxins. Taken 
together with our finding of the strong potency of TSG-6 against lymphocyte 
proliferation in Chapter 2, it suggests TSG-6 may become a promising novel 
therapy for GVHD based on its function to both promote HSC recovery and 
suppress immune rejection, especially for allogeneic transplants.  
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